

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



01 APR 2004



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031233 A2

(51) International Patent Classification⁷: **C07K 14/52**,
C12N 15/19, A61K 38/19, A01K 67/027, G01N 33/53,
C12Q 1/68, A61K 31/7088, C12N 15/62, 15/11

(21) International Application Number:
PCT/EP2003/050668

(22) International Filing Date:
29 September 2003 (29.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02022270.9 4 October 2002 (04.10.2002) EP

(71) Applicant (for all designated States except US): AP-
PLIED RESEARCH SYSTEMS ARS HOLDING N.V.
[NL/NL]; Pietermaai 15, Curacao (AN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **IBBERSON**,
Mark [GB/CH]; Chemin Planet 41, CH-1188 Gimel
(CH). **POWER, Christine** [GB/FR]; Rue des Jonquilles
10, F-01710 Thoiry (FR). **FRAUENSCHUH, Achim**
[DE/CH]; Chemin de Voirets 1, CH-1228 Plan-les-Ouates
(CH).

(74) Agent: **SERONO INTERNATIONAL SA INTELLEC-
TUAL PROPERTY**; Chemin des Aulx 12, CH-1228 Plan-
les-Ouates (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

(48) Date of publication of this corrected version:
17 June 2004

(15) Information about Correction:
see PCT Gazette No. 25/2004 of 17 June 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL CHEMOKINE-LIKE POLYPEPTIDES

(57) Abstract: The present invention discloses open reading frames (ORFs) in human genome encoding for novel chemokines-like polypeptides, and reagents related thereto including variants, mutants and fragments of said polypeptides, as well as ligands and antagonists directed against them. The invention provides methods for identifying and making these molecules, for preparing pharmaceutical compositions containing them, and for using them in the diagnosis, prevention and treatment of diseases.



WO 2004/031233 A2

- 1 -

NOVEL CHEMOKINE-LIKE POLYPEPTIDES

FIELD OF THE INVENTION

The present invention relates to nucleic acid sequences identified in human
5 genome as encoding for novel polypeptides, more specifically for chemokine-like
polypeptides.

BACKGROUND OF THE INVENTION

The mammalian immune response is based on a series of complex, network-like
10 interactions involving cellular components (such as lymphocytes or granulocytes) and
soluble proteins, capable of modulating cellular activities (movement, proliferation,
differentiation, etc.). Thus, there is considerable interest in the isolation and
characterization of cell modulating factors, with the purpose of providing significant
advancements in the diagnosis, prevention, and therapy of human disorders, in
15 particular the ones associated to the immune system.

Chemokines are amongst these soluble proteins, since they are involved in the
directional migration and activation of cells. This superfamily of small (70-130 amino
acids), secreted, heparin-binding, pro-inflammatory proteins is known especially for the
role in the extravasation of leukocytes from the blood to tissue localizations needing the
20 recruitment of these cells (Baggiolini M et al., 1997; Yoshie OF et al., 2001; Fernandez
EJ and Lolis E, 2002).

Chemokines are not only functionally related but also structurally related, since
they all contain a central region in which conserved Cysteines form intramolecular
bonds. In particular, the number and the position of the most N-terminal of these
25 conserved Cysteines in the mature polypeptides is the basic criteria for the generally

- 2 -

recognized classification of chemokines, essentially divided between chemokines having a single or adjacent Cysteines (C-C chemokines), or chemokines having two Cysteines separated by 1-3 amino acids (C-X-C chemokines).

A series of membrane receptors, all heptahelical G-protein coupled receptors, are
5 the binding partners that allow chemokines to exert their biological activity on the target cells. The physiological effects of chemokines result from a complex and integrated system of concurrent interactions. Different cells can present specific combinations of receptors according to their state and/or type. Moreover, chemokine receptors often have overlapping ligand specificity, so that a single receptor can bind different
10 chemokines, as well a single chemokine can bind different receptors, still at high affinity.

Usually chemokines are produced at the site of an injury, inflammation, or other tissue alteration, and exert their activity in a paracrine or autocrine fashion. However, cell-type specific migration and activation in inflammatory and immune processes is not
15 the sole activity of chemokines. Other physiological activities, such as hematopoiesis or angiogenesis, and pathological conditions, such as metastasis, transplant rejection, Alzheimer's disease or atherosclerosis, appear to be regulated by, at least, some of these proteins. In fact, chemokines and/or their receptors have been found considerably over-expressed and/or activated in several animal models or clinical
20 samples (Haskell CA et al., 2002; Lucas AD and Greaves DR, 2001; Frederick MJ and Clayman GL, 2001; Godessart N and Kunkel SL, 2001; Reape TJ and Groot PH, 1999).

There are potential drawbacks in using chemokines as therapeutic agents (tendency to aggregate and promiscuous binding, in particular), but molecules having
25 antagonistic properties against chemokines are widely considered as offering valuable

- 3 -

opportunities for therapeutic intervention in disorders associated to excessive chemokine activities. The inhibition of specific chemokines and their receptors is considered a solution for preventing undesirable or uncontrolled cellular processes, such as recruitment or activation (Baggiolini M, 2001; Proudfoot A, 2000 ; Rossi DF and
5 Zlotnik A, 2000).

The extensive sequencing programs and bioinformatics have made available a large amount of tools and information on human genome and physiology (Quinn-Senger KE et al., 2002; Browne MJ, 2000). Such technologies were also used for discovering novel chemokines and receptors possibly providing new and useful
10 therapeutic molecules and targets. Initially, chemokines genes were regularly mapped on chromosomes 4 and 17, in gene-rich areas of human genome (Nomiya H et al., 2001), but the literature provides various approaches for characterizing novel chemokines by comparing the tissue-distribution of transcripts. Chemokines are usually expressed in lymphoid and other tissues but novel chemokines can have specific
15 expression patterns and can be mapped to chromosomal loci different from the traditional gene clusters (WO 02/70706; Wells TN and Peitsch MC, 2000; Chantry DF et al., 1998; Rossi D et al., 1997).

Novel chemokines have been identified by applying strict homology criteria to known chemokines. However, since the actual content in polypeptide-encoding
20 sequence in human genome for chemokines (as for any other protein family) is still unknown, the possibility still exists to identify DNA sequence encoding for polypeptides having chemotactic activities by applying alternative criteria in the analysis of Open Reading Frames (ORFs, that is, DNA sequences containing consecutive coding triplets of nucleotides, not interrupted by a termination codon and that can be potentially
25 translated in a polypeptide) present in human genome.

- 4 -

SUMMARY OF THE INVENTION

The invention is based upon the identification of Open Reading Frames (ORFs) in human genome encoding novel chemokine-like polypeptides.

Accordingly, the invention provides isolated polypeptides having the amino acid sequence given by SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16, and their mature forms, variants, and fragments, as polypeptides having chemotactic activity. The invention includes also the nucleic acids encoding them, vectors containing such nucleic acids, and cell containing these vectors or nucleic acids, as well as other related reagents such as fusion proteins, ligands, and antagonists.

The invention provides methods for identifying and making these molecules, for preparing pharmaceutical compositions containing them, and for using them in the diagnosis, prevention and treatment of diseases.

DESCRIPTION OF THE FIGURES

Figure 1: alignment of the ORF contained in the DNA sequence GNSQ_1754 (SEQ ID NO: 1) with the protein sequence p1754 (SEQ ID NO: 2). The predicted N-terminal signal sequence is boxed. The predicted C-terminal alpha helix is underlined. The codons matching the original selection criteria are indicated with §. The arrows indicate the position of the primers CL_1754_5 (forward) and CL_1754_3 (reverse) in the ORF sequence.

Figure 2: alignment of the ORF contained in the DNA sequence GNSQ_0711 (SEQ ID NO: 3) with the protein sequence p0711 (SEQ ID NO: 4). The predicted N-terminal signal sequence is boxed. The predicted C-terminal alpha helix is underlined. The codons matching the original selection criteria are indicated

- 5 -

with §. The arrows indicate the position of the primers CL_0711_5 (forward) and CL_0711_3 (reverse) in the ORF sequence.

Figure 3: alignment of the ORF contained in the DNA sequence GNSQ_2882 (SEQ ID NO: 5) with the protein sequence p2882 (SEQ ID NO: 6). The predicted N-terminal signal sequence is boxed. The predicted C-terminal alpha helix is underlined. The codons matching the original selection criteria are indicated with §.

Figure 4: alignment of the ORF contained in the DNA sequence GNSQ_4711 (SEQ ID NO: 7) with the protein sequence p4711 (SEQ ID NO: 8). The predicted N-terminal signal sequence is boxed. The predicted C-terminal alpha helix is underlined. The codons matching the original selection criteria are indicated with §.

Figure 5: alignment of the ORF contained in the DNA sequence GNSQ_4320 (SEQ ID NO: 9) with the protein sequence p4320 (SEQ ID NO: 10). The predicted N-terminal signal sequence is boxed. The predicted C-terminal alpha helix is underlined. The codons matching the original selection criteria are indicated with §. The arrows indicate the position of the primers CL_4320_5 (forward) and CL_4320_3 (reverse) in the ORF sequence.

Figure 6: alignment of the ORF contained in the DNA sequence GNSQ_5008 (SEQ ID NO: 11) with the protein sequence p5008 (SEQ ID NO: 12). The predicted N-terminal signal sequence is boxed. The predicted C-terminal alpha helix is underlined. The codons matching the original selection criteria are indicated with §. The arrows indicate the position of the primers CL_5008_5 (forward) and CL_5008_3 (reverse) in the ORF sequence.

- 6 -

Figure 7: alignment of the ORF contained in the DNA sequence GNSQ_0210 (SEQ ID NO: 13) with the protein sequence p0210 (SEQ ID NO: 14). The predicted N-terminal signal sequence is boxed. The predicted C-terminal alpha helix is underlined. The codons matching the original selection criteria are indicated with §. The arrows indicate the position of the primers CL_0210_5 (forward) and CL_0210_3 (reverse) in the ORF sequence.

Figure 8: alignment of the ORF contained in the DNA sequence GNSQ_4922 (SEQ ID NO: 15) with the protein sequence p4922 (SEQ ID NO: 16). The predicted N-terminal signal sequence is boxed. The predicted C-terminal alpha helix is underlined. The codons matching the original selection criteria are indicated with §. The arrows indicate the position of the primers CL_4922_5 (forward) and CL_4922_3 (reverse) in the ORF sequence.

Figure 9: alignment of human CXCL chemokines with the CXC chemokine-like protein sequences of the invention p1754 (SEQ ID NO: 2), p0711 (SEQ ID NO: 4), p2882 (SEQ ID NO: 6), p0210 (SEQ ID NO: 14), and p4922 (SEQ ID NO: 16). The following human CXCL chemokines have been considered: CXCL1 (SWISSPROT Acc. N° P09341), CXCL2 (SWISSPROT Acc. N° P19875), CXCL3 (SWISSPROT Acc. N° NP_002081), CXCL4 (SWISSPROT Acc. N° NP_002610), CXCL5 (SWISSPROT Acc. N° P42830), CXCL6 (SWISSPROT Acc. N° P80162), CXCL7 (SWISSPROT Acc. N° P02775), CXCL8 (SWISSPROT Acc. N° P10145), CXCL9 (SWISSPROT Acc. N° Q07325), CXCL10 (SWIS SPROT Acc. N° P02778), CXCL11 (SWISSPROT Acc. N° O14625). The protein sequences are divided according to the structure of the three main regions: the N-terminal region (containing the signal sequence), the central Cys-rich region (containing the conserved Cysteines matching the

- 7 -

original selection criteria and indicated with §), and the C-terminal region (containing the predicted alpha helix).

Figure 10: alignment of human CCL chemokines with the CXC chemokine-like protein sequences of the invention p4711 (SEQ ID NO: 8), p4320 (SEQ ID NO: 10), and GNSQ_5008 (SEQ ID NO: 12). The following human CCL chemokines have been considered: CCL1 (SWISSPROT Acc. N° P22362), CCL2 (SWISSPROT Acc. N° P13500), CCL3 (SWISSPROT Acc. N° P10147), CCL4 (SWISSPROT Acc. N° P13236), CCL5 (SWISSPROT Acc. N° P13501), CCL7 (SWISSPROT Acc. N° P80098), CCL8 (SWISSPROT Acc. N° P80075). The protein sequences are divided according to the structure of the three main regions: the N-terminal region (containing the signal sequence), the central Cys-rich region (containing the conserved Cysteines matching the original selection criteria and indicated with §), and the C-terminal region (containing the predicted alpha helix).

Figure 11: Map of the pEAK12d expression vector.

DETAILED DESCRIPTION OF THE INVENTION

The main object of the present invention is to provide novel, isolated polypeptides

having chemotactic activity selected from the group consisting of:

- a) the amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16;
- b) the mature form of the polypeptides SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16;
- c) the polypeptides comprising the Cysteine-rich region of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16, as indicated in fig. 9 and 10;
- d) the active variant of the amino acid sequence given by SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16 wherein any amino acid specified in the chosen sequence is

- 8 -

non-conservatively substituted, provided that no more than 15% of the amino acid residues in the sequence are so changed;

e) the active fragments, precursors, salts, or derivatives of the amino acid sequences given in a) to d).

5 The novel polypeptides p1754 (SEQ ID NO: 2), p0711 (SEQ ID NO: 4), p2882 (SEQ ID NO: 6), p4711 (SEQ ID NO: 8), p4320 (SEQ ID NO: 10), p5008 (SEQ ID NO: 12), p0210 (SEQ ID NO: 14), and p4922 (SEQ ID NO: 16) were identified on the basis of a consensus sequence for human chemokines in which the number and the position of selected amino acids (initial methionine, cysteines, and hydrophobic residues) are
10 defined for protein sequence having length comparable to known chemokines.

The totality of amino acid sequences obtained by translating the known ORFs in the human genome were challenged using this consensus sequence, and the positive hits were further screened for the presence of predicted specific structural and functional "signatures" (a N-terminal signal sequence and a C-terminal alpha helix),
15 and finally selected by comparing sequence features with known chemokines. Therefore, the novel polypeptides of the invention can be predicted to have chemotactic activities.

The terms "active" and "activity" refer to the chemotactic-like properties predicted for the chemokine-like amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16 in
20 the present patent application.

Protein sequences having the indicated number of non-conservative substitutions can be identified using commonly available bioinformatic tools (Mulder NJ and Apweiler R, 2002; Rehm BH, 2001).

In addition to such sequences, a series of polypeptides forms part of the
25 disclosure of the invention. Being chemokines known to go through maturation

- 9 -

processes including the proteolytic removal of N-terminal sequences (by signal peptidases and other proteolytic enzymes), the present patent application also claim the mature form of the polypeptides SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16. As mature form is intended any polypeptide showing chemotactic activity and resulting from *in vivo* (by the expressing cells or animals) or *in vitro* (by modifying the purified polypeptides with specific enzymes) post-translational maturation processes. Mature forms of chemokines resulting from C-terminal processing are also known (Ehlert JE et al., 1998). Other alternative mature forms can also result from the addition of chemical groups such as sugars or phosphates.

10 A further group of polypeptides of the invention are the polypeptides comprising the Cysteine-rich region of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16, as indicated in fig. 9 and 10, since the central Cysteine-rich region contains the essential structural and functional groups of chemokines.

Other claimed polypeptides are the active variants of the amino acid sequences given by SEQ ID NO: 2, 4, 6, 8, 10, 12 14, or 16 wherein any amino acid specified in the chosen sequence is non-conservatively substituted, provided that no more than 15% of the amino acid residues in the sequence are so changed. The indicated percentage has to be measured over the novel amino acid sequences disclosed in figures 1-8, and in particular over a segment of at least 40 amino acids containing the Cysteine-rich regions as indicated in figures 9 and 10.

20 In accordance with the present invention, any substitution should be preferably a "conservative" or "safe" substitution, which is commonly defined a substitution introducing an amino acids having sufficiently similar chemical properties (e.g. a basic, positively charged amino acid should be replaced by another basic, positively charged

- 10 -

amino acid), in order to preserve the structure and the biological function of the molecule.

The literature provide many models on which the selection of conservative amino acids substitutions can be performed on the basis of statistical and physico-chemical studies on the sequence and/or the structure of proteins (Rogov SI and Nekrasov AN, 2001). Protein design experiments have shown that the use of specific subsets of amino acids can produce foldable and active proteins, helping in the classification of amino acid "synonymous" substitutions which can be more easily accommodated in protein structure, and which can be used to detect functional and structural homologs and paralogs (Murphy LR et al., 2000). The groups of synonymous amino acids and the groups of more preferred synonymous amino acids are shown in Table I.

Active variants having comparable, or even improved, activity with respect of corresponding chemokines may result from conventional mutagenesis technique of the encoding DNA, from combinatorial technologies at the level of encoding DNA sequence (such as DNA shuffling, phage display/selection), or from computer-aided design studies, followed by the validation for the desired activities as described in the prior art.

Specific, non-conservative mutations can be also introduced in the polypeptides of the invention with different purposes. Mutations reducing the affinity of the chemokine-like polypeptide for a receptor may increase its ability to be reused and recycled, potentially increasing its therapeutic potency (Robinson CR, 2002). Immunogenic epitopes eventually present in the polypeptides of the invention can be exploited for developing vaccines (Stevanovic S, 2002), or eliminated by modifying their sequence following known methods for selecting mutations for increasing protein

- 11 -

stability, and correcting them (van den Burg B and Eljssink V, 2002; WO 02/05146, WO 00/34317, WO 98/52976).

Further alternative polypeptides of the invention are active fragments, precursors, salt, or derivative of the amino acid sequences the above described sequences .

5 Fragments should present deletions of terminal or internal amino acids not altering their function, and should involve generally a few amino acids, e.g., under ten, and preferably under three, without removing or displacing amino acids which are critical to the functional conformation of the proteins.

10 The "precursors" are compounds which can be converted into the compounds of present invention by metabolic and enzymatic processing prior or after the administration to the cells or to the body.

15 The term "salts" herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of the polypeptides of the present invention. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example, salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids such as, for example, acetic acid or oxalic acid. Any
20 of such salts should have substantially similar activity to the peptides and polypeptides of the invention or their analogs.

25 The term "derivatives" as herein used refers to derivatives which can be prepared from the functional groups present on the lateral chains of the amino acid moieties or on the amino- or carboxy-terminal groups according to known methods. Such molecules can result also from other modifications which do not normally alter primary

- 12 -

sequence, for example *in vivo* or *in vitro* chemical derivatization of polypeptides (acetylation or carboxylation), those made by modifying the pattern of phosphorylation (introduction of phosphotyrosine, phosphoserine, or phosphothreonine residues) or glycosylation (by exposing the polypeptide to mammalian glycosylating enzymes) of a peptide during its synthesis and processing or in further processing steps. Alternatively, derivatives may include esters or aliphatic amides of the carboxyl-groups and N-acyl derivatives of free amino groups or O-acyl derivatives of free hydroxyl-groups and are formed with acyl-groups as for example alkanoyl- or aryl-groups.

The generation of the derivatives may involve a site-directed modification of an appropriate residue, in an internal or terminal position. The residues used for attachment should they have a side-chain amenable for polymer attachment (i.e., the side chain of an amino acid bearing a functional group, e.g. lysine, aspartic acid, glutamic acid, cysteine, histidine, etc.). Alternatively, a residue having a side chain amenable for polymer attachment can replace an amino acid of the polypeptide, or can be added in an internal or terminal position of the polypeptide. Also, the side chains of the genetically encoded amino acids can be chemically modified for polymer attachment, or unnatural amino acids with appropriate side chain functional groups can be employed. The preferred method of attachment employs a combination of peptide synthesis and chemical ligation. Advantageously, the attachment of a water-soluble polymer will be through a biodegradable linker, especially at the amino-terminal region of a protein. Such modification acts to provide the protein in a precursor (or "pro-drug") form, that, upon degradation of the linker releases the protein without polymer modification.

Polymer attachment may be not only to the side chain of the amino acid naturally occurring in a specific position of the antagonist or to the side chain of a natural or

- 13 -

unnatural amino acid that replaces the amino acid naturally occurring in a specific position of the antagonist, but also to a carbohydrate or other moiety that is attached to the side chain of the amino acid at the target position. Rare or unnatural amino acids can be also introduced by expressing the protein in specifically engineered bacterial strains (Bock A, 2001).

Variants of the polypeptides above indicated can be naturally occurring, being identified in organisms other than humans, or resulting from the translation of a single nucleotide polymorphism. Alternatively, artificial variants can be prepared by chemical synthesis, by site-directed mutagenesis techniques, or any other known technique suitable thereof, which provide a finite set of substantially corresponding mutated or shortened peptides or polypeptides which can be routinely obtained and tested by one of ordinary skill in the art using the teachings presented in the prior art.

The novel amino acid sequences disclosed in the present patent application can be used to provide different kind of reagents and molecules. Examples of these compounds are binding proteins or antibodies that can be identified using their full sequence or specific fragments, such as antigenic determinants. Peptide libraries can be used in known methods (Tribbick G, 2002) for screening and characterizing antibodies or other proteins binding the claimed amino acid sequences, and for identifying alternative forms of such polypeptides having similar binding properties.

The present patent application discloses also fusion proteins comprising any of the polypeptides described above. These polypeptides should contain protein sequence heterologous to the one disclosed in the present patent application, without significantly impairing the chemotactic activity and possibly providing additional properties. Examples of such properties are an easier purification procedure, a longer lasting half-life in body fluids, an additional binding moiety, the maturation by means of

- 14 -

an endoproteolytic digestion, or extracellular localization. This latter feature is of particular importance for defining a specific group of fusion or chimeric proteins included in the above definition since it allows the claimed molecules to be localized in the space where not only isolation and purification of these polypeptides is facilitated, but also where generally chemokines and their receptor interact.

Design of the moieties, ligands, and linkers, as well methods and strategies for the construction, purification, detection and use of fusion proteins are disclosed in the literature (Nilsson J et al., 1997; Methods Enzymol, Vol. 326-328, Academic Press, 2000). The preferred protein sequences that can be comprised in the fusion proteins of the invention belong to these protein sequences: membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins, export signal-containing proteins. Features of these sequences and their specific uses are disclosed in a detailed manner, for example, for albumin fusion proteins (WO 01/77137), fusion proteins including multimerization domain (WO 01/02440, WO 00/24782, WO 94/10308, WO 97/30161), immuno-conjugates (Garnett MC, 2001), or fusion protein including sequences allowing the purification of the recombinant products by affinity chromatography (Constans A, 2002; Burgess RR and Thompson NE, 2002; Lowe CR et al., 2001; Sheibani N, 1999).

Several studies on structure-activity features of chemokines indicate that these proteins bind and activate receptors by making use of the amino-terminal region. Proteolytic digestion, mutagenesis, or chemical modifications directed to amino acids in this region can generate compounds having antagonistic activity (Loetscher P and Clark-Lewis I, 2001; Lambeir A et al., 2001, Proost P et al., 2001). Thus, antagonistic molecules resulting from specific modifications (deletions, non-conservative substitutions, addition of chemical groups) of one or more residues in the amino-

- 15 -

terminal region or in other regions of the corresponding chemokine are considered having therapeutic potential for inflammatory and autoimmune diseases (WO 02/28419; WO 00/27880; WO 99/33989; Schwarz MK and Wells T, 1999). Therefore, a further object of the present patent application is represented by such kind of antagonists generated by modifying the polypeptides of the invention.

The polypeptides of the invention can be used to generate and characterize ligands binding specifically to them. These molecules can be natural or artificial, very different from the chemical point of view (binding proteins, antibodies, molecularly imprinted polymers), and can be produced by applying the teachings in the art (WO 02/74938; Kuroiwa Y et al., 2002; Haupt K, 2002; van Dijk MA and van de Winkel JG, 2001; Gavilondo JV and Larrick JW, 2000). Such ligands can antagonize or inhibit the chemotactic activity of the polypeptide against which they have been generated. In particular, common and efficient ligands are represented by extracellular domain of a membrane-bound protein or antibodies, which can be in the form monoclonal, polyclonal, humanized antibody, or an antigen-binding fragment.

The polypeptides and the polypeptide-based derived reagents described above can be in alternative forms, according to the desired method of use and/or production, such as active conjugates or complexes with a molecule chosen amongst radioactive labels, fluorescent labels, biotin, or cytotoxic agents.

Specific molecules, such as peptide mimetics, can be also designed on the sequence and/or the structure of a polypeptide of the invention. Peptide mimetics (also called peptidomimetics) are peptides chemically modified at the level of amino acid side chains, of amino acid chirality, and/or of the peptide backbone. These alterations are intended to provide agonists or antagonists of the polypeptides of the invention with improved preparation, potency and/or pharmacokinetics features.

- 16 -

For example, when the peptide is susceptible to cleavage by peptidases following injection into the subject is a problem, replacement of a particularly sensitive peptide bond with a non-cleavable peptide mimetic can provide a peptide more stable and thus more useful as a therapeutic. Similarly, the replacement of an L-amino acid residue is a standard way of rendering the peptide less sensitive to proteolysis, and finally more similar to organic compounds other than peptides. Also useful are amino-terminal blocking groups such as t-butyloxycarbonyl, acetyl, theyl, succinyl, methoxysuccinyl, suberyl, adipyl, azelayl, dansyl, benzyloxycarbonyl, fluorenylmethoxycarbonyl, methoxyazelayl, methoxyadipyl, methoxysuberyl, and 2,4-dinitrophenyl. Many other modifications providing increased potency, prolonged activity, easiness of purification, and/or increased half-life are disclosed in the prior art (WO 02/10195; Villain M et al., 2001).

Preferred alternative, synonymous groups for amino acids derivatives included in peptide mimetics are those defined in Table II. A non-exhaustive list of amino acid derivatives also include aminoisobutyric acid (Aib), hydroxyproline (Hyp), 1,2,3,4-tetrahydro-isoquinoline-3-COOH, indoline-2carboxylic acid, 4-difluoro-proline, L-thiazolidine-4-carboxylic acid, L-homoproline, 3,4-dehydro-proline, 3,4-dihydroxy-phenylalanine, cyclohexyl-glycine, and phenylglycine.

By "amino acid derivative" is intended an amino acid or amino acid-like chemical entity other than one of the 20 genetically encoded naturally occurring amino acids. In particular, the amino acid derivative may contain substituted or non-substituted, linear, branched, or cyclic alkyl moieties, and may include one or more heteroatoms. The amino acid derivatives can be made *de novo* or obtained from commercial sources (Calbiochem-Novabiochem AG, Switzerland; Bachem, USA).

- 17 -

Various methodologies for incorporating unnatural amino acids derivatives into proteins, using both *in vitro* and *in vivo* translation systems, to probe and/or improve protein structure and function are disclosed in the literature (Dougherty DA, 2000). Techniques for the synthesis and the development of peptide mimetics, as well as non -
5 peptide mimetics, are also well known in the art (Golebiowski A et al., 2001; Hruby VJ and Balse PM, 2000; Sawyer TK, in "Structure Based Drug Design", edited by Veerapandian P, Marcel Dekker Inc., pg. 557-663, 1997).

Another object of the present invention are isolated nucleic acids encoding for the polypeptides of the invention having chemotactic activity, the polypeptides binding to
10 an antibody or a binding protein generated against them, the corresponding fusion proteins, or mutants having antagonistic activity as disclosed above. Preferably, these nucleic acids should comprise a DNA sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, or 15, or the complement of said DNA sequences.

Alternatively, the nucleic acids of the invention should hybridize under high
15 stringency conditions, or exhibits at least about 85% identity over a stretch of at least about 30 nucleotides, with a nucleic acid selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, or 15 or a complement of said DNA sequences. A further object of the present invention is therefore the polypeptides encoded by these purified nucleic acids.

20 The wording "high stringency conditions" refers to conditions in a hybridization reaction that facilitate the association of very similar molecules and consist in the overnight incubation at 60°-65°C in a solution comprising 50 % formamide, 5X SSC (150 m M NaCl, 15 m M trisodium citrate), 50 mM sodium phosphate (p H 7.6), 5x Denhardt's solution, 10 % dextran sulphate, and 20 microgram/ml denatured, sheared

- 18 -

salmon sperm DNA, followed by washing the filters in 0.1X SSC at the same temperature.

These nucleic acids, including nucleotide sequences substantially the same, can be comprised in plasmids, vectors and any other DNA construct which can be used for maintaining, modifying, introducing, or expressing the encoded polypeptide. In particular, vectors wherein said nucleic acid molecule is operatively linked to expression control sequences can allow expression in prokaryotic or eukaryotic host cells of the encoded polypeptide.

The wording "nucleotide sequences substantially the same" includes all other nucleic acid sequences that, by virtue of the degeneracy of the genetic code, also code for the given amino acid sequences. In this sense, the literature provides indications on preferred or optimized codons for recombinant expression (Kane JF et al., 1995).

The nucleic acids and the vectors can be introduced into cells with different purposes, generating transgenic cells and organisms. A process for producing cells capable of expressing a polypeptide of the invention comprises genetically engineering cells with such vectors and nucleic acids.

In particular, host cells (e.g. bacterial cells) can be modified by transformation for allowing the transient or stable expression of the polypeptides encoded by the nucleic acids and the vectors of the invention. Alternatively, said molecules can be used to generate transgenic animal cells or non-human animals (by non- / homologous recombination or by any other method allowing their stable integration and maintenance), having a constitutive or inducible altered expression levels (i.e. enhanced or reduced) of the polypeptides of the invention, when the level is compared with the normal expression levels. Such precise modifications can be obtained by making use of the nucleic acids of the inventions and of technologies associated, for

- 19 -

example, to gene therapy (Meth. Enzymol., vol. 346, 2002) or to site-specific recombinases (Kolb AF, 2002). Model systems based on the chemokine-like polypeptides disclosed in the present patent application for the systematic study of their function can be also generated by gene targeting into human cell lines (Bunz F, 2002).

5 The polypeptides of the invention can be prepared by any method known in the art, including recombinant DNA-related technologies, and chemical synthesis technologies. In particular, a method for making a polypeptide of the invention may comprise culturing a host or transgenic cell as described above under conditions in which the nucleic acid or vector is expressed, and recovering the polypeptide encoded
10 by said nucleic acid or vector from the culture. For example, when the vector expresses the polypeptide as a fusion protein with an extracellular or signal-peptide containing proteins, the recombinant product can be secreted in the extracellular space, and can be more easily collected and purified from cultured cells in view of further processing or, alternatively, the cells can be directly used or administered.

15 The DNA sequence coding for the proteins of the invention can be inserted and ligated into a suitable episomal or non- / homologously integrating vectors, which can be introduced in the appropriate host cells by any suitable means (transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, etc.). Factors of importance in selecting a particular
20 plasmid or viral vector include: the ease with which recipient cells that contain the vector, may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.

- 20 -

The vectors should allow the expression of the isolated or fusion protein including the polypeptide of the invention by prokaryotic or eukaryotic host cells under the control of transcriptional initiation / termination regulatory sequences, which are chosen to be constitutively active or inducible in said cell. A cell line substantially enriched in such cells can be then isolated to provide a stable cell line.

Different transcriptional and translational regulatory sequences may be employed for eukaryotic hosts (e.g. yeasts, insect, plant, or mammalian cells), depending on the nature of the host. They may be derived from viral sources, such as adenovirus, bovine papilloma virus, Simian virus or the like, where the regulatory signals are associated with a particular gene which has a high level of expression. Examples are the TK promoter of the Herpes virus, the SV40 early promoter, the yeast GAL4 gene promoter, etc. Transcriptional initiation regulatory signals may be selected which allow for repression and activation, so that expression of the genes can be modulated. The cells stably transformed by the introduced DNA can be selected by introducing one or more markers allowing the selection of host cells that contain the expression vector. The marker may also provide for phototrophy to an auxotrophic host, biocide resistance, e.g. antibiotics, or heavy metals such as copper, or the like. The selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection.

Host cells may be either prokaryotic or eukaryotic. Preferred are eukaryotic hosts, e.g. mammalian cells, such as human, monkey, mouse, and Chinese Hamster Ovary (CHO) cells, because they provide post-translational modifications to proteins, including correct folding and glycosylation. Also yeast cells can carry out post-translational peptide modifications including glycosylation. A number of recombinant DNA strategies exist which utilize strong promoter sequences and high copy number of

- 21 -

plasmids that can be utilized for production of the desired proteins in yeast. Yeast recognizes leader sequences in cloned mammalian gene products and secretes peptides bearing leader sequences (i.e., pre-peptides).

The above mentioned embodiments of the invention can be achieved by combining the disclosure provided by the present patent application on the sequence of novel chemokine-like polypeptides with the knowledge of common molecular biology techniques.

Many books and reviews provides teachings on how to clone and produce recombinant proteins using vectors and prokaryotic or eukaryotic host cells, such as some titles in the series "A Practical Approach" published by Oxford University Press ("DNA Cloning 2: Expression Systems", 1995; "DNA Cloning 4: Mammalian Systems", 1996; "Protein Expression", 1999; "Protein Purification Techniques", 2001).

Moreover, updated and more focused literature provides an overview of the technologies for expressing polypeptides in a high-throughput manner (Chambers SP, 2002; Coleman TA, et al., 1997), of the cell systems and the processes used industrially for the large-scale production of recombinant proteins having therapeutic applications (Andersen DC and Krummen L, 2002; Chu L and Robinson DK, 2001), and of alternative eukaryotic expression systems for expressing the polypeptide of interest, which may have considerable potential for the economic production of the desired protein, such the ones based on transgenic plants (Giddings G, 2001) or the yeast *Pichia pastoris* (Lin Cereghino GP et al., 2002). Recombinant protein products can be rapidly monitored with various analytical technologies during purification to verify the amount and the quantity of the expressed polypeptides (Baker KN et al., 2002), as well as to check if there is problem of bioequivalence and immunogenicity (Schellekens H, 2002; Gendel SM, 2002).

- 22 -

Totally synthetic chemokines are disclosed in the literature (Brown A et al., 1996), and many examples of chemical synthesis technologies, which can be effectively applied for the chemokine-like polypeptides of the invention given their short length, are available in the literature, as solid phase or liquid phase synthesis technologies. for example, the amino acid corresponding to the carboxy-terminus of the peptide to be synthesized is bound to a support which is insoluble in organic solvents, and by alternate repetition of reactions, one wherein amino acids with their amino groups and side chain functional groups protected with appropriate protective groups are condensed one by one in order from the carboxy-terminus to the amino-terminus, and one where the amino acids bound to the resin or the protective group of the amino groups of the peptides are released, the peptide chain is thus extended in this manner.

Solid phase synthesis methods are largely classified by the tBoc method and the Fmoc method, depending on the type of protective group used. Typically used protective groups include tBoc (t-butoxycarbonyl), Cl-Z (2-chlorobenzyloxycarbonyl), Br-Z (2-bromobenzyloxycarbonyl), Bzl (benzyl), Fmoc (9-fluorenylmethoxycarbonyl), Mbh (4,4'-dimethoxydibenzhydryl), Mtr (4-methoxy-2,3,6-trimethylbenzenesulphonyl), Trt (trityl), Tos (tosyl), Z (benzyloxycarbonyl) and Cl₂-Bzl (2,6-dichlorobenzyl) for the amino groups; NO₂ (nitro) and Pmc (2,2,5,7,8-pentamethylchromane-6-sulphonyl) for the guanidino groups; and tBu (t-butyl) for the hydroxyl groups). After synthesis of the desired peptide, it is subjected to the de-protection reaction and cut out from the solid support. Such peptide cutting reaction may be carried with hydrogen fluoride or tri-fluoromethane sulfonic acid for the Boc method, and with TFA for the Fmoc method.

The purification of the polypeptides of the invention can be carried out by any one of the methods known for this purpose, i.e. any conventional procedure involving extraction, precipitation, chromatography, electrophoresis, or the like. A further

- 23 -

purification procedure that may be used in preference for purifying the protein of the invention is affinity chromatography using monoclonal antibodies or affinity groups, which bind the target protein and which are produced and immobilized on a gel matrix contained within a column. Impure preparations containing the proteins are passed
5 through the column. The protein will be bound to the column by heparin or by the specific antibody while the impurities will pass through. After washing, the protein is eluted from the gel by a change in pH or ionic strength. Alternatively, HPLC (High Performance Liquid Chromatography) can be used. The elution can be carried using a water-acetonitrile-based solvent commonly employed for protein purification.

10 The disclosure of the novel polypeptides of the invention, and the reagents disclosed in connection to them (antibodies, nucleic acids, cells) allows also to screen and characterize compounds that enhance or reduce their expression level into a cell or in an animal. Examples of compounds that can reduce or block the expression of the chemokine-like polypeptides are antisense oligonucleotides (Stein CA, 2001) or small
15 interfering, double stranded RNA molecules that can trigger RNA interference-mediated silencing (Paddison PJ et al., 2002; Lewis DL et al., 2002). These compounds are intended as antagonists (in addition to the ones above described in connection to mutants and ligands) in the context of the possible mechanism of antagonism for blocking cytokine/chemokine-controlled pathways as defined in the
20 literature (Choy EH and Panayi GS, 2001; Dower SK, 2000).

"Oligonucleotides" refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands that may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A
25 synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

- 24 -

The invention includes purified preparations of the compounds of the invention (polypeptides, nucleic acids, cells, etc.). Purified preparations, as used herein, refers to the preparations containing at least 1%, preferably at least 5%, by dry weight of the compound of the invention.

5 The present patent application discloses a series of novel chemokine-like polypeptides and of related reagents having several possible applications. In particular, whenever an increase in the chemotactic activity of a polypeptide of the invention is desirable in the therapy or in the prevention of a disease, reagents such as the disclosed chemokine-like polypeptides, the corresponding fusion proteins and peptide
10 mimetics, the encoding nucleic acids, the expressing cells, or the compounds enhancing their expression can be used.

Therefore, the present invention discloses pharmaceutical compositions for the treatment or prevention of diseases needing an increase in the chemotactic activity of a polypeptide of the invention, which contain one of the disclosed chemokine-like
15 polypeptides, the corresponding fusion proteins and peptide mimetics, the encoding nucleic acids, the expressing cells, or the compounds enhancing their expression, as active ingredient.

The process for the preparation of these pharmaceutical compositions comprises combining the disclosed chemokine-like polypeptides, the corresponding fusion
20 proteins and peptide mimetics, the encoding nucleic acids, the expressing cells, or the compounds enhancing their expression, together with a pharmaceutically acceptable carrier.

Methods for the treatment or prevention of diseases needing an increase in the chemotactic activity of a polypeptide of the invention, comprise the administration of a
25 therapeutically effective amount of the disclosed chemokine-like polypeptides, the

- 25 -

corresponding fusion proteins and peptide mimetics, the encoding nucleic acids, the expressing cells, or the compounds enhancing their expression.

Amongst the reagents disclosed in the present patent application, the ligands, the antagonists or the compounds reducing the expression or the activity of polypeptides of the invention have several applications, and in particular they can be used in the therapy or in the diagnosis of a disease associated to the excessive chemotactic activity of a polypeptide of the invention.

Therefore, the present invention discloses pharmaceutical compositions for the treatment or prevention of diseases associated to the excessive chemotactic activity of a polypeptide of the invention, which contain one of the ligands, antagonists, or compounds reducing the expression or the activity of such polypeptides, as active ingredient.

The process for the preparation of these pharmaceutical compositions comprises combining the ligand, the antagonist, or the compound, together with a pharmaceutically acceptable carrier.

Methods for the treatment or prevention of diseases associated to the excessive chemotactic activity of the polypeptide of the invention comprise the administration of a therapeutically effective amount of the antagonist, the ligand or of the compound.

The pharmaceutical compositions of the invention may contain, in addition to chemokine-like polypeptide or to the related reagent, suitable pharmaceutically acceptable carriers, biologically compatible vehicles and additives which are suitable for administration to an animal (for example, physiological saline) and eventually comprising auxiliaries (like excipients, stabilizers, adjuvants, or diluents) which facilitate the processing of the active compound into preparations which can be used pharmaceutically.

- 26 -

The pharmaceutical compositions may be formulated in any acceptable way to meet the needs of the mode of administration. For example, of biomaterials, sugar - macromolecule conjugates, hydrogels, polyethylene glycol and other natural or synthetic polymers can be used for improving the active ingredients in terms of drug
5 delivery efficacy. Technologies and models to validate a specific mode of administration are disclosed in literature (Davis BG and Robinson MA, 2002; Gupta P et al., 2002; Luo B and Prestwich GD, 2001; Cleland JL et al., 2001; Pillai O and Panchagnula R, 2001).

Polymers suitable for these purposes are biocompatible, namely, they are non -
10 toxic to biological systems, and many such polymers are known. Such polymers may be hydrophobic or hydrophilic in nature, biodegradable, non-biodegradable, or a combination thereof. These polymers include natural polymers (such as collagen, gelatin, cellulose, hyaluronic acid), as well as synthetic polymers (such as polyesters, polyorthoesters, polyanhydrides). Examples of hydrophobic non-degradable polymers
15 include polydimethyl siloxanes, polyurethanes, polytetrafluoroethylenes, polyethylenes, polyvinyl chlorides, and polymethyl methacrylates. Examples of hydrophilic non-degradable polymers include poly(2-hydroxyethyl methacrylate), polyvinyl alcohol, poly(N-vinyl pyrrolidone), polyalkylenes, polyacrylamide, and copolymers thereof. Preferred polymers comprise as a sequential repeat unit ethylene oxide, such as
20 polyethylene glycol (PEG).

Any accepted mode of administration can be used and determined by those skilled in the art to establish the desired blood levels of the active ingredients. For example, administration may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, oral, or
25 buccal routes. The pharmaceutical compositions of the present invention can also be

- 27 -

administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, and the like, for the prolonged administration of the polypeptide at a predetermined rate, preferably in unit dosage forms suitable for single administration of precise dosages.

5 Parenteral administration can be by bolus injection or by gradual perfusion over time. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions, which may contain auxiliary agents or excipients known in the art, and can be prepared according to routine methods. In addition, suspension of the active compounds as appropriate oily injection suspensions
10 may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions that may contain substances increasing the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
15 Optionally, the suspension may also contain stabilizers. Pharmaceutical compositions include suitable solutions for administration by injection, and contain from about 0.01 to 99.99 percent, preferably from about 20 to 75 percent of active compound together with the excipient.

 The wording "therapeutically effective amount" refers to an amount of the active
20 ingredients that is sufficient to affect the course and the severity of the disease, leading to the reduction or remission of such pathology. The effective amount will depend on the route of administration and the condition of the patient.

 The wording "pharmaceutically acceptable" is meant to encompass any carrier, which does not interfere with the effectiveness of the biological activity of the active
25 ingredient and that is not toxic to the host to which is administered. For example, for

- 28 -

parenteral administration, the above active ingredients may be formulated in unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution. Carriers can be selected also from starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the various oils, including those of petroleum, animal, vegetable or synthetic origin (peanut oil, soybean oil, mineral oil, sesame oil).

It is understood that the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The dosage will be tailored to the individual subject, as is understood and determinable by one of skill in the art. The total dose required for each treatment may be administered by multiple doses or in a single dose. The pharmaceutical composition of the present invention may be administered alone or in conjunction with other therapeutics directed to the condition, or directed to other symptoms of the condition. Usually a daily dosage of active ingredient is comprised between 0.01 to 100 milligrams per kilogram of body weight per day. Ordinarily 1 to 40 milligrams per kilogram per day given in divided doses or in sustained release form is effective to obtain the desired results. Second or subsequent administrations can be performed at a dosage, which is the same, less than, or greater than the initial or previous dose administered to the individual.

Apart from the methods having a therapeutic or a production purpose, several other methods can make use of the chemokine-like polypeptides and of the related reagents disclosed in the present patent application.

- 29 -

In a first example, a method for screening candidate compounds effective to treat a disease related to a chemokine-like polypeptides of the invention, comprises:

- (a) contacting host cells expressing such polypeptide, transgenic non-human animals, or transgenic animal cells having enhanced or reduced expression levels of the polypeptide, with a candidate compound; and
- (b) determining the effect of the compound on the animal or on the cell.

In a second example, a method for identifying a candidate compound as an antagonist/inhibitor or agonist/activator of a polypeptide of the invention comprises:

- (a) contacting the polypeptide, the compound, and a mammalian cell or a mammalian cell membrane; and
- (b) measuring whether the molecule blocks or enhances the interaction of the polypeptide, or the response that results from such interaction, with the mammalian cell or the mammalian cell membrane.

In a third example, methods for determining the activity and/or the presence of the polypeptide of the invention in a sample, can detect either the polypeptide or the encoding RNA/DNA. Thus, such a method comprises:

- (a) providing a protein-containing sample;
- (b) contacting said sample with a ligand of the invention; and
- (c) determining the presence of said ligand bound to said polypeptide, thereby determining the activity and/or the presence of polypeptide in said sample.

Alternatively, the method comprises:

- (a) providing a nucleic acids-containing sample;
- (b) contacting said sample with a nucleic acid of the invention; and
- (c) determining the hybridization of said nucleic acid with a nucleic acid into the sample, thereby determining the presence of the nucleic acid in the sample.

- 30 -

In this context, primer sequences containing the sequences SEQ ID NO: 17-28 (Table III) can be used as well for determining the presence or the amount of a transcript or of a nucleic acid encoding a polypeptide of invention in a sample by means of Polymerase Chain Reaction amplification.

5 A further object of the present invention are kits for measuring the activity and/or the presence of chemokine-like polypeptide of the invention in a sample comprising one or more of the reagents disclosed in the present patent application: a chemokine-like polypeptide of the invention, an antagonist, ligand or peptide mimetic, an isolated nucleic acid or the vector, a pharmaceutical composition, an expressing cell, a
10 compound increasing or decreasing the expression levels, and/or primer sequences containing the sequences SEQ ID NO: 17-28.

Those kits can be used for *in vitro* diagnostic or screenings methods, and their actual composition should be adapted to the specific format of the sample (e.g. biological sample tissue from a patient), and the molecular species to be measured.
15 For example, if it is desired to measure the concentration of the chemokine-like polypeptide, the kit may contain an antibody and the corresponding protein in a purified form to compare the signal obtained in Western blot. Alternatively, if it is desired to measure the concentration of the transcript for the chemokine-like polypeptide, the kit may contain a specific nucleic acid probe designed on the corresponding ORF
20 sequence, or may be in the form of nucleic acid array containing such probe, or the primer sequences disclosed as SEQ ID NO: 17-28 (Table III). The kits can be also in the form of protein-, peptide mimetic-, or cell-based microarrays (Templin MF et al., 2002; Pellois JP et al., 2002; Blagoev B and Pandey A, 2001); allowing high-throughput proteomics studies, by making use of the proteins, peptide mimetics and cells
25 disclosed in the present patent application.

- 31 -

The novel chemokine-like polypeptides of the invention and the related reagents that may be useful, as active ingredients in pharmaceutical compositions appropriately formulated, in the treatment or prevention of diseases such as cell proliferative disorders, autoimmune/inflammatory disorders, cardiovascular disorders, neurological disorders, developmental disorders, metabolic disorder, infections and other pathological conditions. In particular, given the known properties of chemokines, the disclosed polypeptides and reagents should address conditions involving abnormal or defective cell migration. Non-limitative examples of such conditions are the following: arthritis, rheumatoid arthritis (RA), psoriatic arthritis, osteoarthritis, systemic lupus erythematosus (SLE), systemic sclerosis, scleroderma, polymyositis, glomerulonephritis, fibrosis, lung fibrosis and inflammation, allergic or hypersensitivity diseases, dermatitis, asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), Crohn's diseases, ulcerative colitis, multiple sclerosis, septic shock, HIV infection, transplant rejection, wound healing, metastasis, endometriosis, hepatitis, liver fibrosis, cancer, analgesia, and vascular inflammation related to atherosclerosis.

The therapeutic applications of the polypeptides of the invention and of the related reagents can be evaluated (in terms of safety, pharmacokinetics and efficacy) by the means of the *in vivo* or *in vitro* assays making use of animal cell, tissues and models (Coleman RA et al., 2001; Li AP, 2001; Methods Mol. Biol. vol. 138, "Chemokines Protocols", edited by Proudfoot A et al., Humana Press Inc., 2000; Methods Enzymol, vol. 287 and 288, Academic Press, 1997), or by the means of *in silico*, computational approaches (Johnson DE and Wolfgang GH, 2000), known for the validation of chemokines and other biological products during drug discovery and preclinical development.

- 32 -

All publications, patents and patent applications cited herein are incorporated in full by reference for all purposes.

The invention will now be described with reference to the specific embodiments by means of the following Examples, which should not be construed as in any way limiting the present invention. The content of the description comprises all modifications and substitutions which can be practiced by a person skilled in the art in light of the above teachings and, therefore, without extending beyond the meaning and purpose of the claims.

10

EXAMPLES

Example 1: Selection of chemokine-like open reading frames (ORFs) from human genome

Perl (Practical Extraction and Report Language) is a programming language having powerful pattern matching functions into large text data files allowing the extraction of information from genomic DNA sequences, starting from an alpha-numerical expression describing a defined consensus sequence (Stein LD, 2001).

A Perl script was used to retrieve novel open reading frames (ORFs), having chemokine-like features, in a FASTA-formatted sequence file containing the NCBI genome (build 28). After translating the genomic DNA sequence into the six possible reading frames (3 forward and 3 reverse), each of these translated sequences was then tested for a match against a pattern designed to detect to chemokine-like proteins, which was elaborated comparing multiple sequence alignments of known chemokines. The following pattern, fitting all the aligned sequences, was adopted:

25

- 33 -

{M}-{X}₃₋₁₂ -{L or I or V}₁₋₃ -{X}₀₋₂ -{L or I or V}₂₋₄ -{X}₀₋₂ -{L or I or V}₁₋₃ - {X}₁₀₋₃₀ -{C}-(X)₀₋₃ -C- (X)₂₀₋₄₀ - C -{X}₁₂₋₂₀ -{C} -{X}₁₅₋₄₀ STOP

The letter(s) between brackets represented alternative amino acids (in one-letter code) which should be present the number of times indicated in subscript characters. This expression, which describes the entire family of sequences on the basis of the respective positioning of the initial methionine, hydrophobic residues, and conserved cysteines on the linear sequence, can be transformed in Perl language as follows:

M[[^]]{3,12}[LIV]{1,3}[[^]]{0,2}[LIV]{2,4}[[^]]{0,2}[LIV]{1,3}[[^]]{10,30}C[[^]]{0,3}C[[^]]{20,40}C[[^]]{12,20}C[[^]]{15,40}[^{*}]

A total of FASTA-formatted 7974 ORFs matching the pattern were compared to known proteins present in protein databases (SwissProt/Trembl and Derwent GENESEQ) using a rapid searching program for local alignments between a query and a hit sequence based on Basic Local Alignment Search Tool (BLAST, BLASTX) and ClustalW algorithms (Altschul SF et al., 1990; Pearson WR and Miller W, 1992; Gish W and States DJ, 1993). BLAST parameters used were: Comparison matrix = BLOSUM62; word length = 3; .E value cutoff = 10; Gap opening and extension = default; No filter.

The sequences obtained from this first screening were further selected using additional criteria. 2441 ORFs showing at least 70% of homology with known proteins in protein databases were eliminated. The remaining 5533 ORFs were filtered using 2 neural network-based algorithms developed for the prediction (probability at least 0.7) of a N-terminal signal peptide and of an alpha helix secondary structure having at least

- 34 -

5 amino acids within the C-terminal 30 amino acids (a hallmark of the IL8-like fold) with high confidence. The resulting 253 ORFs, which were predicted as containing these features, were transformed in text format and were compared to known chemokines, searching manually for the best alignments. This further refinement, based on the qualitative assessment of the alignments, led to the selection of eight chemokine-like encoding ORFs for which all criteria for the prediction (sequence length, cysteine spacing, N-terminal signal sequence, C-terminal alpha helix) were fulfilled, making them comparable to known chemokines.

The DNA sequence GNSQ_1754 (SEQ ID NO: 1), belonging to human chromosome 13, contains an ORF encoding for the 98-amino acid long protein sequence p1754 (SEQ ID NO: 2), which, according to the prediction, presents a 22-amino acid long signal sequence and an alpha helix covering the residues 70-79 (figure 1).

The DNA sequence GNSQ_0711 (SEQ ID NO: 3), belonging to human chromosome 16, contains an ORF encoding for the 109-amino acid long protein sequence p0711 (SEQ ID NO: 4), which, according to the prediction, presents a 17-amino acid long signal sequence and an alpha helix covering the residues 98-106 (figure 2).

The DNA sequence GNSQ_2882 (SEQ ID NO: 5), belonging to human chromosome 6, contains an ORF encoding for the 107-amino acid long protein sequence p2882 (SEQ ID NO: 6), which, according to the prediction, presents a 18-amino acid long signal sequence and an alpha helix covering the residues 96-104 (figure 3).

The DNA sequence GNSQ_4711 (SEQ ID NO: 7), belonging to human chromosome 3, contains an ORF encoding for the 102-amino acid long protein

- 35 -

sequence p4711 (SEQ ID NO: 8), which, according to the prediction, presents a 22 - amino acid long signal sequence and an alpha helix covering the residues 83-97 (figure 4).

5 The DNA sequence GNSQ_4320 (SEQ ID NO: 9), belonging to human chromosome 3, contains an ORF encoding for the 101-amino acid long protein sequence p4320 (SEQ ID NO: 10), which, according to the prediction, presents a 16-amino acid long signal sequence and an alpha helix covering the residues 90-98 (figure 5).

10 The DNA sequence GNSQ_5008 (SEQ ID NO: 11), belonging to human chromosome 12, contains an ORF encoding for the 112-amino acid long protein sequence p5008 (SEQ ID NO: 12), which, according to the prediction, presents a 17 - amino acid long signal sequence and an alpha helix covering the residues 95-109 (figure 6).

15 The DNA sequence GNSQ_0210 (SEQ ID NO: 13), belonging to human chromosome 7, contains an ORF encoding for the 127-amino acid long protein sequence p0210 (SEQ ID NO: 14), which, according to the prediction, presents a 16 - amino acid long signal sequence and an alpha helix covering the residues 94-113 (figure 7).

20 The DNA sequence GNSQ_4922 (SEQ ID NO: 15), belonging to human chromosome 10, contains an ORF encoding for the 91-amino acid long protein sequence p4922 (SEQ ID NO: 14), which, according to the prediction, presents a 23 - amino acid long signal sequence and an alpha helix covering the residues 67-74 (figure 8).

25 Amongst these sequences characterized as encoding chemokine-like polypeptides, five of them (p1754, p0711, p2882, p0210, and p4922) present a central

- 36 -

Cys-rich region in which the first two Cysteines are separated by 1-3 amino acids, and can be compared with known G-X-C chemokines (figure 9). The remaining three sequences (p4711, p4320, and p5008) present two adjacent Cysteines at the beginning of such region, and therefore can be compared with known C-C chemokines (figure 10).

Example 2: Cloning of the novel chemokine-like ORFs from human genomic DNA

Six of the eight above-defined chemokine-like ORFs (GNSQ_1754, GNSQ_4922, GNSQ_5008, GNSQ_0210, GNSQ_0711, and GNSQ_4320) were first cloned from human genomic DNA into a cloning vector, and then transferred into an expression vector using Polymerase Chain Reaction (PCR), with pairs of forward / reverse primers specific for each ORF (see arrows in figure 1, 2, and 5-8).

The cloning primers (CL series; Table III), having a length comprised between 19 and 25 bases, were designed for amplifying each ORF, using human genomic DNA as template. The forward primers start from the initial ATG or a few nucleotides before. The reverse primers are complementary to the 3' end of the ORF, including the stop codon.

The PCR was performed by mixing the following components in each ORF-specific reaction (total volume of 50 μ l in double-distilled water):

- 150 ng human genomic DNA (Clontech)
- 1.2 μ M primers (0.6 μ M each primer)
- 240 μ M dNTP (Invitrogen)
- 0.5 μ l AmpliTaq (2.5 Units; Applied Biosystems)
- 5 μ l AmpliTaq buffer 10X (Applied Biosystems)

- 37 -

The PCR reactions were performed using an initial denaturing step of 94 °C for 2 minutes, followed by 30 cycles:

94°C for 30 seconds

55°C for 30 seconds

5 72°C for 30 seconds

After a final elongation step of 72°C for 10 minutes, the PCR products were directly subcloned into the pCRII-TOPO vector using the TOPO™ cloning system (Invitrogen), according to manufacturer's standard protocol. The TOPO cloning system is a variation of the TA cloning system allowing the rapid cloning of PCR products, taking advantage from the fact that Taq polymerase leaves a single Adenosine at the 3' end of PCR products. Since the TOPO vector has single-stranded Thymine overhangs, Topoisomerase I enzyme is able to join the T-ends of the vector to the A-overhangs of the PCR product, which can be used without any purification step.

The resulting plasmids (pCRTOPO-ORF series) were used to transform *E. coli* cells (TOP10F', Invitrogen, supplied with the TOPO TA Cloning Kit), obtaining several clones for each ORF. Plasmid DNA was isolated using a commercial kit (WIZARD Plasmid Minipreps; Promega) and sequenced to verify the identity of the amplified and cloned sequence with the originally selected human genomic DNA sequence.

The plasmids containing the desired sequences were used in a further round of PCR reactions necessary for transferring the ORFs into the expression vector pEAK12d (figure 11), which allows the expression of the cloned insert under the control of EF-1α promoter and in frame with a 6-Histidine Tag sequence, using the Gateway cloning system (Invitrogen).

The expression vector pEAK12D was constructed by modifying pEAK12 (Edge Biosystems). This vector was digested with HindIII and NotI, made blunt ended with

- 38 -

Klenow and dephosphorylated using calf-intestinal alkaline phosphatase. After dephosphorylation, the vector was ligated to blunt ended Gateway reading frame cassette C (Gateway vector conversion system, Invitrogen cat no. 11828-019) that contains AttR recombination sites flanking the ccdB gene (marker for negative selection of non-recombinant plasmids) and chloramphenicol resistance. The resulting plasmids were used to transform DB3.1 *E. coli* cells, which allow propagation of vectors containing the ccdB gene. Miniprep DNA was isolated from several of the resultant colonies and digested with AseI / EcoRI to identify clones yielding a 670 bp fragment, obtainable only when the cassette had been inserted in the correct orientation. The resultant plasmid was called pEAK12D.

Two series of primers (Table IV) were designed to add the ATTB1 and ATTB2 recombination sites (necessary for the integration in the expression vector) at the 5' and 3' end, respectively, of the ORF-containing insert. In the first series of primers (EX1 series), the original ORF-specific CL primers were modified by adding, at the 5' end, the sequence AAGCAGGCTTCGCCACC (for forward primers) or GTGATGGTGATGGTG (for reverse primers, but after eliminating the nucleotides complementary to the stop codon). In the second series of primers (EX2 series), the original ORF-specific CL primers were modified by adding, at the 5' end, the sequence GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC (for forward primers) or GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATGGTGATGGTG (for reverse primers, but after eliminating the nucleotides complementary to the stop codon). These reverse primers contain the codons for the 6-Histidine tag, which then results fused in frame with the ORFs at their C-terminal end.

- 39 -

The PCR amplification was performed in 2 consecutive reactions. The first one was performed by mixing the following components (total volume 50 μ l in double-distilled water):

25 ng pCRTPOPO-ORF vector
5mM dNTP (Invitrogen)
0.5 μ l Pfx DNA polymerase (Invitrogen)
0.5 μ l each EX1 primer (100 μ M)
5 μ l Pfx polymerase buffer 10X (Invitrogen)

The PCR reactions were performed using an initial denaturing step of 95°C for 2 minutes, followed by 10 cycles:

94°C for 15 seconds
68°C for 30 seconds

The PCR products were purified using the Wizard PCR prep DNA purification system (Promega), and added as templates in a second PCR reaction including the following components (total volume 50 μ l in double-distilled water):

10 μ l purified PCR product
5mM dNTP (Invitrogen)
0.5 μ l Pfx DNA polymerase (Invitrogen)
0.5 μ l each EX2 primer (100 μ M)
5 μ l Pfx polymerase buffer 10X (Invitrogen)

The PCR reactions were performed an initial denaturing step of 95°C for 1 minute, followed by 4 cycles:

94°C for 15 seconds
50°C for 30 seconds
68°C for 3 minutes 30 seconds

- 40 -

Then the following conditions were applied for 25 cycles:

94°C for 15 seconds

55°C for 30 seconds

68°C for 3 minutes 30 seconds.

5 The DNA fragments resulting from the PCR reactions were purified as described before and recombined into the pEAK12d vector using the Gateway system.

First, the following 10 µl reactions were assembled:

	pDONR-201 (0.1 µg/µl)	1.5 µl
	PCR product	5 µl
10	BP buffer	2 µl
	BP enzyme mix	1.5 µl

After being incubated at room temperature for 1 hour, the reaction was stopped by adding proteinase K (1 µl, 2 µg) and incubating at 37°C for further 10 minutes.

15 An aliquot of this reaction (2 µl) was used for transforming *E. coli* cells (strain DH10B) by electroporation. Plasmid DNA was prepared for 4 clones for each ORF and used for parallel 10 µl recombination reactions containing:

	pEAK12d (0.1 µg / µl)	1.5 µl
	Plasmid DNA	1.5 µl
	ddH2O	3.5 µl
20	LR buffer	2 µl
	LR enzyme mix	1.5 µl

After being incubated at room temperature for 1 hour, the reaction was stopped by adding proteinase K (1 µl, 2 µg) and incubating at 37°C for further 10 minutes. An aliquot of this reaction (1 µl) was used for transforming DH10B *E. coli* cells by
25 electroporation. The clones containing the correct insert were identified first by

- 41 -

performing colony PCR on 3 colonies using the forward and reverse vector primers pEAK12d F1 (GCCAGCTTGGCACTTGATGT) and pEAK12d R1 (GATGGAGGTGGACGTGTCAG), then confirmed by sequencing the insert with the same primer.

5

Example 3: Expression and purification of the 6-Histidine-tagged chemokine-like polypeptides in mammalian cells

Human Embryonic Kidney cells expressing the Epstein-Barr virus Nuclear Antigen (HEK293-EBNA) were seeded in T225 flasks (50 ml at a density of 2×10^5 cells/ml) from 16 to 20 hours prior to transfection, which was performed using the cationic polymer reagent JetPEI™ (PolyPlus-transfection; 2 μ l/ μ g of plasmid DNA). For each flask, 113 μ g of the ORF-specific pEAK12d plasmid, which were prepared using CsCl (Sambrook, J et al. "Molecular Cloning, a laboratory manual"; 2nd edition. 1989; Cold Spring Harbor Laboratory Press), were co-transfected with 2.3 μ g of a plasmid acting as positive control since it expresses Green Fluorescent Protein (GFP). The plasmids, diluted in 230 μ l of JetPEI™ solution, were added to 4.6 ml of NaCl 150 mM, vortexed and incubated for 30 minutes at room temperature. This transfection mix was then added to the T225 flask and incubated at 37°C for 6 days. An aliquot of the cultures was then exposed to UV irradiation to check the transfection efficiency by evaluating GFP fluorescence.

20

Culture medium from HEK293-EBNA cells transfected with the same plasmids were pooled and 100 ml of the medium were diluted to 200 ml with 100 ml of ice-cold buffer A (50 mM NaH_2PO_4 ; 600 mM NaCl; 8.7 % (w/v) glycerol, pH 7.5), which is the same buffer used for equilibrating the affinity column on which His-tagged proteins were subsequently immobilized and eluted. The solution was filtered through a 0.22 μ m

25

- 42 -

sterile filter (Millipore) and kept at 4°C in 250 ml sterile square media bottles until further processing.

Two consecutive chromatography procedures were applied to the samples at 4°C using an HPLC-based system (Perfusion Chromatography™, PerSeptive Biosystems) including a VISION workstation (BioCAD™ series), POROS™ chromatographic media, and an external 250 ml-sample loader (Labomatic).

In the first chromatography step, a Ni-metal affinity column (0.83 ml, POROS 20 MC) was first regenerated with 30 column volumes of EDTA solution (100 mM EDTA; 1 M NaCl; pH 8.0), and then recharged with Ni ions through washing with 15 column volumes of the Ni solution (100 mM NiSO₄). The column is subsequently washed with 10 column volumes of buffer A, 7 column volumes of buffer B (50 mM NaH₂PO₄; 600 mM NaCl; 8.7 % (w/v) glycerol, 400 mM; imidazole, pH 7.5), and finally equilibrated with 15 column volumes of buffer A containing 15 mM imidazole. The sample loader charged the protein-containing solution onto the Ni metal affinity column at a flow rate of 10 ml/min. The column was then washed with 12 column volumes of Buffer A, followed by 28 column volumes of Buffer A containing a concentration of imidazole (20 mM) allowing the elution of contaminating proteins that are loosely attached to the Ni-column. The His-tagged protein is finally eluted with 10 column volumes of Buffer B at a flow rate of 2 ml/min, collecting collected 1.6 ml fractions.

In the second chromatography step, a gel-filtration column (10 ml G-25 Sephadex) was regenerated with 2 ml of buffer D (137 mM NaCl; 2.7 mM KCl; 1.5 mM KH₂PO₄; 8 mM Na₂HPO₄; 1 M NaCl; pH 7.2), and then equilibrated with 2 column volumes of buffer C (137 mM NaCl; 2.7 mM KCl; 1.5 mM KH₂PO₄; 8 mM Na₂HPO₄; 20 % (w/v) glycerol; pH 7.4) before injecting the Ni-column peak fractions onto this column. The sample is eluted with buffer C and the desalted sample is recovered in 2.2

- 43 -

ml fractions. The peak fractions from the gel-filtration column were filtered through a 0.22 μ m sterile centrifugation filter (Millipore) and aliquots (20 μ l) were analyzed in parallel on SDS-PAGE (4-12 % NuPAGE gel; Novex) by Coomassie staining and by Western blot with antibodies recognizing Histidine tags. Protein concentrations were
5 determined in the samples that show detectable protein bands by Coomassie staining, using the BCA Protein Assay kit (Pierce) and Bovine Serum Albumin as standard.

The gel for the Western blot analysis was electrotransferred to a nitrocellulose membrane at 290 mA at 4°C for 1 hour. The membrane is blocked with 5 % milk powder in PBS (137 mM NaCl; 2.7 mM KCl; 1.5 mM KH₂PO₄; 8 mM Na₂HPO₄; pH 7.4),
10 and subsequently incubated with a mixture of 2 rabbit polyclonal anti-Histidine tag antibodies (G-18 and H-15, 0.2 μ g/ml each; Santa Cruz) at 4°C overnight. After a further 1 hour incubation at room temperature, the membrane was washed with PBS containing 0.1% Tween-20 (3 x 10 min), and then exposed to a secondary HRP-conjugated anti-rabbit antibody (DAKO) at room temperature for 2 hours. After washing
15 in PBS containing 0.1% Tween-20 (3 x 10 minutes), the ECL kit (Amersham Pharmacia) was used to detect the antibodies immobilized onto the membrane, comparing the film with the image of the Coomassie stained gel.

**Example 4: Cell- and Animal-based assay for the validation and characterization
20 of the chemokine-like polypeptides.**

Several assays have been developed for testing specificity, potency, and efficacy of chemokines using cell cultures or animal models, for example *in vitro* chemotaxis assays (Proudfoot AE et al., 2001; Lusti-Narasimhan M et al., 1995), or mouse ear swelling (Garrigue JL et al., 1994). Many other assays and technologies for
25 generating useful tools and products (antibodies, transgenic animals, radiolabeled

- 44 -

proteins, etc.) have been described in reviews and books dedicated to chemokines (Methods Mol. Biol. vol. 138, "Chemokines Protocols", edited by Proudfoot AI et al., Humana Press Inc., 2000; Methods Enzymol, vol. 287 and 288, Academic Press, 1997), and can be used to verify, in a more precise manner, the biological activities of
5 the chemokine-like polypeptides of the invention and related reagents in connection with possible therapeutic or diagnostic methods and uses.

- 45 -

TABLE I

Amino Acid	Synonymous Groups	More Preferred Synonymous Groups
Ser	Gly, Ala, Ser, Thr, Pro	Thr, Ser
Arg	Asn, Lys, Gln, Arg, His	Arg, Lys, His
Leu	Phe, Ile, Val, Leu, Met	Ile, Val, Leu, Met
Pro	Gly, Ala, Ser, Thr, Pro	Pro
Thr	Gly, Ala, Ser, Thr, Pro	Thr, Ser
Ala	Gly, Thr, Pro, Ala, Ser	Gly, Ala
Val	Met, Phe, Ile, Leu, Val	Met, Ile, Val, Leu
Gly	Ala, Thr, Pro, Ser, Gly	Gly, Ala
Ile	Phe, Ile, Val, Leu, Met	Ile, Val, Leu, Met
Phe	Trp, Phe, Tyr	Tyr, Phe
Tyr	Trp, Phe, Tyr	Phe, Tyr
Cys	Ser, Thr, Cys	Cys
His	Asn, Lys, Gln, Arg, His	Arg, Lys, His
Gln	Glu, Asn, Asp, Gln	Asn, Gln
Asn	Glu, Asn, Asp, Gln	Asn, Gln
Lys	Asn, Lys, Gln, Arg, His	Arg, Lys, His
Asp	Glu, Asn, Asp, Gln	Asp, Glu
Glu	Glu, Asn, Asp, Gln	Asp, Glu
Met	Phe, Ile, Val, Leu, Met	Ile, Val, Leu, Met
Trp	Trp, Phe, Tyr	Trp

- 46 -

TABLE II

Amino Acid	Synonymous Groups
Ser	D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D-Cys
Arg	D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-.Met, D-Ile, Orn, D-Orn
Leu	D-Leu, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met
Pro	D-Pro, L-l-thioazolidine-4-carboxylic acid, D-or L-1-oxazolidine-4-carboxylic acid
Thr	D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val
Ala	D-Ala, Gly, Aib, B-Ala, Acp, L-Cys, D-Cys
Val	D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met, AdaA, AdaG
Gly	Ala, D-Ala, Pro, D-Pro, Aib, .beta.-Ala, Acp
Ile	D-Ile, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met
Phe	D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, AdaA, AdaG, cis-3,4, or 5-phenylproline, Bpa, D-Bpa
Tyr	D-Tyr, Phe, D-Phe, L-Dopa, His, D-His
Cys	D-Cys, S--Me--Cys, Met, D-Met, Thr, D-Thr
Gln	D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp
Asn	D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln
Lys	D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn
Asp	D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln
Glu	D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln
Met	D-Met, S--Me--Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val

- 47 -

TABLE III

SEQ ID NO:	NAME	DIRECTION	5' ->3' SEQUENCE
17	CL_1754_5	Forward	ATGAATGTCATTGTTTACA
18	CL_1754_3	Reverse	CTACCAACCT GTACAGCATG
19	CL_4922_5	Forward	CTGACTATGATGAGGGTGCT AAGGC
20	CL_4922_3	Reverse	TCAAATTGCTGGGAAAGTTC TCAGG
21	CL_5008_5	Forward	CATGATCTTTGGCCTGCTAA TC
22	CL_5008_3	Reverse	TTAAAGGGAA AGTAATAGGA G
23	CL_0210_5	Forward	CTATGGGCTTTGTGTCTA TG
24	CL_0210_3	Reverse	TCAGAAAAATTCTAACAAA TTG
25	CL_0711_5	Forward	ATGGTTATTCCACATCTTG
26	CL_0711_3	Reverse	TCATCTCTGTTGCAGCAAAC G
27	CL_4320_5	Forward	ATGTTATTTACTTTATTATT C
28	CL_4320_3	Reverse	TCACAGAAAA ATCAAAGAGG

- 48 -

TABLE IV

SEQ ID NO:	NAME	DIRECTION	5' -3' SEQUENCE
29	EX1_1754_5	Forward	AAGCAGGCTTCGCCACC ATGAATGTCATTGTTTACA
30	EX1_1754_3	Reverse	GTGATGGTGATGGTG CCAACCTGTACAGCATG
31	EX1_4922_5	Forward	AAGCAGGCTTCGCCACC CTGACTATGATGAGGGTGCT AAGGC
32	EX1_4922_3	Reverse	GTGATGGTGATGGTG AATTGCTGGGAAAGTTC TCAGG
33	EX1_5008_5	Forward	AAGCAGGCTTCGCCACC CATGATCTTTGGCCTGCTAA TC
34	EX1_5008_3	Reverse	GTGATGGTGATGGTG AAGGGAAAGTAATAGGA G
35	EX1_0210_5	Forward	AAGCAGGCTTCGCCACC CTATGGGCTTTGTTGTTCTA TG
36	EX1_0210_3	Reverse	GTGATGGTGATGGTG GAAAAATCTAACAAAA TTG
37	EX1_0711_5	Forward	AAGCAGGCTTCGCCACC ATGGTTATTCCACATCTTG
38	EX1_0711_3	Reverse	GTGATGGTGATGGTG TCTCTGTTGCAGCAAAC G
39	EX1_4320_5	Forward	AAGCAGGCTTCGCCACC ATGTTATTTACTTTATTATT C
40	EX1_4320_3	Reverse	GTGATGGTGATGGTG CAGAAAA ATCAAAGAGG
41	EX2_1754_5	Forward	GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC ATGAATGTC ATTGTTTACA
42	EX2_1754_3	Reverse	GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATGGTGA TGGTGCCAACCT GTACAGCATG
43	EX2_4922_5	Forward	GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC CTGACTATG ATGAGGGTGCT AAGGC
44	EX2_4922_3	Reverse	GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATGGTGA TGGTGAATTGCTGGGAAAGTTC TCAGG
45	EX2_5008_5	Forward	GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC CATGATCTT TGGCCTGCTAATC
46	EX2_5008_3	Reverse	GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATGGTGA TGGTGAAGGGAAAGTAATAGGA G
47	EX2_0210_5	Forward	GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC CTATGGGCT TTGTTGTTCTATG
48	EX2_0210_3	Reverse	GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATGGTGA TGGTGAAAAATCTAACAAAA TTG
49	EX2_0711_5	Forward	GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC ATGGTTATT CCACATCTTG
50	EX2_0711_3	Reverse	GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATGGTGA TGGTGTCCTCTGTTGCAGCAAAC G
51	EX2_4320_5	Forward	GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACC ATGTTATTT ACTTTATTATTC
52	EX2_4320_3	Reverse	GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAATGGTGATG GTGA TGGTGCAAAAA ATCAAAGAGG

- 49 -

REFERENCES

- Altschul SF et al., J Mol Biol, 215: 403-10, 1990.
- Andersen DC and Krummen L, Curr Opin Biotechnol, 13: 117-23, 2002.
- Baggiolini M et al., Annu Rev Immunol, 15: 675-705, 1997.
- 5 Baggiolini M, J Intern Med, 250: 91-104, 2001.
- Baker KN et al., Trends Biotechnol, 20: 149-56, 2002.
- Blagoev B and Pandey A, Trends Biochem Sci, 26: 639-41, 2001.
- Bock A, Science, 292: 453-4, 2001.
- Brown A et al., J Pept Sci, 2: 40-46, 1996.
- 10 Browne MJ, J Biotechnol, 78: 247-250, 2000.
- Bunz F, Curr Opin Oncol, 14: 73-8, 2002.
- Burgess RR and Thompson NE, Curr Opin Biotechnol, 12: 450-4, 2001.
- Chambers SP, Drug Disc Today, 14: 759-765, 2002.
- Chantray DF et al., J Leukoc Biol, 64: 49-54, 1998.
- 15 Choy EH and Panayi GS, N Engl J Med, 344: 907-16, 2001.
- Chu L and Robinson DK, Curr Opin Biotechnol, 13: 304-8, 2001.
- Cleland JL et al., Curr Opin Biotechnol, 12: 212-9, 2001.
- Coleman TA et al., Gene 190: 163-171, 1997.
- Coleman RA et al., Drug Discov Today, 6: 1116-1126, 2001.
- 20 Constans A, The Scientist, 16: 37, 2002.
- Davis BG and Robinson MA, Curr Opin Drug Discov Devel, 5: 279-88, 2002.
- Dower SK, Nat Immunol, 1: 367-8, 2000.
- Dougherty DA, Curr Opin Chem Biol, 4: 645-52, 2000.
- Ehlert JE et al., J Immunol, 161: 4975-4982, 1998.
- 25 Fernandez EJ and Lolis E, Annu Rev Pharmacol Toxicol, 42:469-499, 2002.

- 50 -

Frederick MJ and Clayman GL, Exp Rev Mol Med 2001, <http://www-ermm.cbcu.cam.ac.uk/reviews.htm>.

Garnett MC, Adv Drug Deliv Rev, 53: 171-216, 2001.

Garrigue JL et al., Contact Dermatitis, 30: 231-7, 1994.

5 Gavilondo JV and Larrick JW, Biotechniques, 29: 128-136, 2000.

Gendel SM, Ann N Y Acad Sci, 964: 87-98, 2002.

Giddings G, Curr Opin Biotechnol, 12: 450-4, 2001.

Gish W and States DJ, Nat Genet, 3: 266-72, 1993.

Godessart N and Kunkel SL, Curr Opin Immunol, 13: 670-675, 2001.

10 Golebiowski A et al., Curr Opin Drug Discov Devel, 4: 428-34, 2001.

Gupta P et al., Drug Discov Today, 7: 569-579, 2002.

Haskell CA et al., Curr Opin Invest Drugs, 3: 399-455, 2002.

Haupt K, Nat Biotechnol, 20 : 884-885, 2002.

Hruby VJ and Balse PM, Curr Med Chem, 7: 945-70, 2000.

15 Johnson DE and Wolfgang GH, Drug Discov Today, 5: 445-454, 2000.

Kane JF, Curr Opin Biotechnol, 6: 494-500, 1995.

Kolb AF, Cloning Stem Cells, 4: 65-80, 2002.

Kuroiwa Y et al., Nat Biotechnol, 20: 889-94, 2002.

Lambeir A, et al. J Biol Chem, 276: 29839-29845, 2001.

20 Lewis DL, Nat Genet, 32: 107-8, 2002.

Li AP, Drug Discov Today, 6: 357-366, 2001.

Lin Cereghino GP et al., Curr Opin Biotechnol, 13: 329-332, 2001.

Loetscher P and Clark-Lewis I, J Leukoc Biol, 69: 881-884, 2001.

Lowe CR et al., J Biochem Biophys Methods, 49: 561-74, 2001.

- 51 -

Lucas AD and Greaves DR, Exp Rev Mol Med 2001, <http://www-ermm.cbcu.cam.ac.uk/reviews.htm>.

Luo B and Prestwich GD, Exp Opin Ther Patents, 11: 1395-1410, 2001.

Lusti-Narasimhan M et al., J Biol Chem, 270: 2716-21, 1995.

5 Mulder NJ and Apweiler R, Genome Biol, 3(1): REVIEWS2001, 2002

Murphy LR et al., Protein Eng, 13: 149-52, 2000.

Nilsson J et al., Protein Expr Purif, 11: 1-16, 1997.

Nomiyama H et al., Genes Immun, 2: 110-113, 2001.

Paddison PJ, Proc Natl Acad Sci U S A, 99: 1443-8, 2002.

10 Pearson WR and Miller W, Methods Enzymol, 210: 575-601, 1992.

Pellois JP et al., Nat Biotechnol, 20: 922-6, 2002.

Pillai O and Panchagnula R, Cur Opin Chem Biol, 5: 447-451, 2001

Proost P, et al. Blood, 98: 3554-3561, 2001.

Proudfoot A., Immunol Rev, 177: 246-256, 2000.

15 Proudfoot A et al., J Biol Chem 276: 10620-10626, 2001.

Quinn-Senger KE et al., Curr Opin Chem Biol, 6: 418-26, 2002.

Reape TJ and Groot PH, Atherosclerosis, 147:213-25, 1999.

Rehm BH, Appl Microbiol Biotechnol, 57: 579-92, 2001.

Robinson CR, Nat Biotechnol, 20: 879-880, 2002.

20 Rogov SI and Nekrasov AN, Protein Eng, 14: 459-463, 2001.

Rossi D et al., J.Immunol, 158: 1033-1036, 1997.

Rossi D and Zlotnik A, Annu Rev Immunol, 18:217-42, 2000.

Schellekens H, Nat Rev Drug Discov, 1: 457-62, 2002

Schwarz MK and Wells TN, Curr Opin Chem Biol, 3: 407-17, 1999.

25 Sheibani N, Prep Biochem Biotechnol, 29: 77-90, 1999.

- 52 -

Stein CA, J Clin Invest, 108: 641-4, 2001.

Stein LD, Methods Biochem Anal, 43: 413-49, 2001.

Stevanovic S, Nat Rev Cancer, 2: 514-20, 2002.

Templin MF et al., Trends Biotechnol, 20: 160-6, 2002.

5 Tribbick G, J Immunol Methods, 267: 27-35, 2002.

van den Burg B and Eijssink V, Curr Opin Biotechnol, 13: 333-337, 2002.

van Dijk MA and van de Winkel JG, Curr Opin Chem Biol, 5: 368-74, 2001.

Villain M et al., Chem Biol, 8: 673-9, 2001.

Wells TN and Peitsch MC. Methods Mol Biol, 138: 65-73, 2000.

10 Yoshie OF et al., Adv Immunol, 78: 57-110, 2001.

- 53 -

CLAIMS

1. An isolated polypeptide having chemotactic activity selected from the group consisting of:
 - a) the amino acid sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16;
 - 5 b) the mature form of the polypeptides SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16;
 - c) the polypeptides comprising the Cysteine-rich region of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16, as indicated in fig. 9 and 10;
 - d) the active variants of the amino acid sequence given by SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16 wherein any amino acid specified in the chosen
10 sequence is non-conservatively substituted, provided that no more than 15% of the amino acid residues in the sequence are so changed;
 - e) the active fragments, precursors, salts, or derivatives of the amino acid sequences given in a) to d).
- 15 2. The polypeptide of claim 1 that is a naturally occurring allelic variant of the sequence given by SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16.
3. The polypeptide of claim 2, wherein the variant is the translation of a single nucleotide polymorphism.
- 20 4. The polypeptide of any of the claims from 1 to 3, wherein the polypeptide binds specifically an antibody or a binding protein generated against SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16 or a fragment thereof.

- 54 -

5. A fusion protein comprising a polypeptide according to any of the claims from 1 to 4.
6. The fusion proteins of claim 6 wherein said proteins further comprise one or more amino acid sequence belonging to these protein sequences: membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins, export signal-containing proteins.
7. An antagonist of a polypeptide of any of the claims from 1 to 4, wherein said antagonist comprises an amino acid sequence resulting from the modification of one or more residues of said polypeptide.
8. A ligand binding specifically to a polypeptide according to any one of claims 1 to 4.
9. The ligand of claim 8 that antagonizes or inhibits the chemotactic activity of a polypeptide according to any one of claims 1 to 4.
10. A ligand according to claim 11 which is a monoclonal antibody, a polyclonal antibody, a humanized antibody, an antigen binding fragment, or the extracellular domain of a membrane-bound protein.
11. The polypeptides of any of the claims from 1 to 7 or of claim 10, wherein said polypeptides are in the form of active conjugates or complexes with a molecule chosen amongst radioactive labels, fluorescent labels, biotin, or cytotoxic agents.

- 55 -

12. A peptide mimetic designed on the sequence and/or the structure of a polypeptide according to any one of claims 1 to 4.

5 13. An isolated nucleic acid encoding for an isolated polypeptide selected from the group consisting of:

- a) the polypeptides having chemotactic activity of any of the claims from 1 to 4;
- b) the fusion proteins of claim 5 or 6; or
- c) the antagonists of claim 7.

10

14. The nucleic acid of claim 13, comprising a DNA sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, or 15, or the complement of said DNA sequences.

15 15. A purified nucleic acid which:

- a) hybridizes under high stringency conditions, or
- b) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides,

with a nucleic acid selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9,

20

11, 13, or 15, or a complement of said DNA sequences

16. A vector comprising a nucleic acid of any of claims from 13 to 15.

- 56 -

17. The vector of claim 16, wherein said nucleic acid molecule is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic host cells of the encoded polypeptide.
- 5 18. The polypeptides encoded by the purified nucleic acids of claim 15.
19. A process for producing cells capable of expressing a polypeptide of any the claims from 1 to 7 or of claim 18, comprising genetically engineering cells with a vector or a nucleic acid according to any of the claims from 13 to 17.
- 10 20. A host cell transformed with a vector or a nucleic acid according to any of the claims from 13 to 17.
- 15 21. A transgenic animal cell that has been transformed with a vector or a nucleic acid according to any of the claims from 13 to 17, having constitutive or inducible altered expression levels of a polypeptide according to any one of claims from 1 to 4.
- 20 22. A transgenic non-human animal that has been transformed to have enhanced or reduced expression levels of a polypeptide according to any one of claims from 1 to 4.
23. A method for making a polypeptide of any the claims from 1 to 7 comprising culturing a cell of claim 20 or 21 under conditions in which the nucleic acid or

- 57 -

vector is expressed, and recovering the polypeptide encoded by said nucleic acid or vector from the culture.

24. A compound that enhances the expression level of a polypeptide according to
5 any one of claims from 1 to 4 into a cell or in an animal.
25. A compound that reduces the expression level of a polypeptide according to any one of claims from 1 to 4 into a cell or in an animal.
- 10 26. The compound of claim 24 that is an antisense oligonucleotide or a small interfering RNA.
27. Purified preparations containing a polypeptide of any of the claims from 1 to 6 or claim 18, an antagonist of claim 7, a ligand of any of the claims from 8 to 10,
15 peptide mimetic of claim 12, a nucleic acid of any of the claims from 13 to 17, a cell of claim 20 or 21, or a compound of any of the claims from 24 to 26.
28. Use of a polypeptide of any of the claims from 1 to 6 or claim 18, a peptide mimetic of claim 12, a nucleic acid of any of the claims from 13 to 17, a cell of
20 claim 20 or 21, or a compound of claim 24, in the therapy or in the prevention of a disease when the increase in the chemotactic activity of a polypeptide of any of the claims from 1 to 4 is needed.
29. Pharmaceutical compositions for the treatment or prevention of diseases needing
25 an increase in the chemotactic activity of a polypeptide of any of the claims from

- 58 -

1 to 6 or claim 18, a peptide mimetic of claim 12, a nucleic acid of any of the claims from 13 to 17, a cell of claim 20 or 21, or a compound of claim 24, as active ingredient.

5 30. Process for the preparation of pharmaceutical compositions, which comprises combining a polypeptide of any of the claims from 1 to 6 or claim 18, a peptide mimetic of claim 12, a nucleic acid of any of the claims from 13 to 17, a cell of claim 20 or 21, or a compound of claim 24, together with a pharmaceutically acceptable carrier.

10

31. Method for the treatment or prevention of diseases needing an increase in the chemotactic activity of a polypeptide of any of the claims from 1 to 4, comprising the administration of a therapeutically effective amount of a polypeptide of any of the claims from 1 to 6 or claim 18, a peptide mimetic of claim 12, a nucleic acid of
15 any of the claims from 13 to 17, a cell of claim 20 or 21, or a compound of claim 24.

15

32. Use of an antagonist of claim 7, a ligand of any of the claims from 8 to 10, or of a compound of claims 25 or 26, in the therapy or in the prevention of a disease
20 associated to the excessive chemotactic activity of a polypeptide of any of the claims from 1 to 4.

20

33. Pharmaceutical compositions for the treatment or prevention of a disease associated to the excessive chemotactic activity of a polypeptide of any of the

- 59 -

claims from 1 to 4, containing an antagonist of claim 7, a ligand of any of the claims from 8 to 10, or of a compound of claims 25 or 26, as active ingredient.

34. Process for the preparation of pharmaceutical compositions for the treatment or prevention of diseases associated to the excessive chemotactic activity of a polypeptide of any of the claims from 1 to 4, which comprises combining an antagonist of claim 7, a ligand of any of the claims from 8 to 10, or of a compound of claims 25 or 26, together with a pharmaceutically acceptable carrier.
35. A method for the treatment or prevention of diseases related to the polypeptide of any of the claims from 1 to 4, comprising the administration of a therapeutically effective amount of an antagonist of claim 7, a ligand of any of the claims from 8 to 10, or of a compound of claims 25 or 26.
36. A method for screening candidate compounds effective to treat a disease related to the chemokine-like polypeptides of any of the claims from 1 to 4, comprising:
- (a) contacting a cell of claim 20, a transgenic animal cell of claim 21, or a transgenic non-human animal according to claim 22, having enhanced or reduced expression levels of the polypeptide, with a candidate compound and
 - (b) determining the effect of the compound on the animal or on the cell.
37. A method for identifying a candidate compound as an antagonist/inhibitor or agonist/activator of a polypeptide of any of the claims 1 to 4 comprising:
- (a) contacting said polypeptide, said compound, and a mammalian cell or a mammalian cell membrane capable of binding the polypeptide; and

- 60 -

(b) measuring whether the molecule blocks or enhances the interaction of the polypeptide, or the response that results from such interaction, with the mammalian cell or the mammalian cell membrane..

5 38. A method for determining the activity and/or the presence of the polypeptide of any the claims from 1 to 4 in a sample, the method comprising:

- (a) providing a protein-containing sample;
- (b) contacting said sample with a ligand of any of the claims from 8 to 10; and
- (c) determining the presence or said ligand bound to said polypeptide.

10

39. A method for determining the presence or the amount of a transcript or of a nucleic acid encoding the polypeptide of any the claims from 1 to 4 in a sample, the method comprising:

- (a) providing a nucleic acids-containing sample;
- 15 (b) contacting said sample with a nucleic acid of any of the claims 13 to 17; and
- (c) determining the hybridization of said nucleic acid with a nucleic acid into the sample.

40. Use of the primer sequences containing the sequences SEQ ID NO: 17-28 for
20 determining the presence or the amount of a transcript or of a nucleic acid encoding a polypeptide of any the claims from 1 to 4 in a sample by Polymerase Chain Reaction

41. A kit for measuring the activity and/or the presence of the chemokine-like
25 polypeptides of any of the claims from 1 to 4 in a sample comprising one or more

- 61 -

of the following reagents: a polypeptide of any of the claims from 1 to 6 or claim
18, an antagonist of claim 7, a ligand of any of the claims from 8 to 10, a
polypeptide of claim 11, a peptide mimetic of claim 12, a nucleic acid of any of
the claims from 13 to 17, a cell of claim 20 or 21, a compound of any of the
5 claims from 24 to 26, a pharmaceutical composition of claims 29 or 33, or primer
sequences containing the sequences SEQ ID NO: 17-28.

1/11

Figure 1

		<div>forward</div>														
GNSQ_1754	gaggta	atg aat gtc att gtt tta cag ttt att ctt ctt gtg ttt ctt ctt	51													
p1754		<u>Met Asn Val Ile Val Leu Gln Phe Ile Leu Leu Val Phe Leu Leu</u>	15													
		\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$														
GNSQ_1754		gtg aag ata tat aag cat gca gac aca cta ttt tat ata tat ata	96													
p1754		<u>Val Lys Ile Tyr Lys His Ala</u> Asp Thr Leu Phe Tyr Ile Tyr Ile	30													
		\$														
GNSQ_1754		cct ata tat gta tgt atg tgt ata cac agt tat gca ctg tat aac	141													
p1754		Pro Ile Tyr Val Cys Met Cys Ile His Ser Tyr Ala Leu Tyr Asn	45													
		\$ \$														
GNSQ_1754		agt att ttg gtc agt gat gga ctg cgt atg cta agg tgt tcc cat	186													
p1754		Ser Ile Leu Val Ser Asp Gly Leu Arg Met Leu Arg Cys Ser His	60													
		\$														
GNSQ_1754		aag att ata ata agt act ttg act ata act ttt cta tgt tta cat	231													
p1754		Lys Ile Ile Ile Ser Thr Leu Thr Ile <u>Thr Phe Leu Cys Leu His</u>	75													
		\$														
GNSQ_1754		gca gaa ata ctt act aat ggg tta cag ttg cct aca gta ttc agt	276													
p1754		<u>Ala Glu Ile Leu</u> Thr Asn Gly Leu Gln Leu Pro Thr Val Phe Ser	90													
		<div>reverse</div>														
GNSQ_1754		aca cca gca tgc tgt aca ggt tgg tag	303													
p1754		Thr Pro Ala Cys Cys Thr Gly Trp STOP	98													
		\$														

3/11

Figure 3

GNSQ_2882	ggaagt	atg agt cct agt tta ttc ttc att ttt aag att gtt ttg gct att	51
p2882		<u>Met Ser Pro Ser Leu Phe Phe Ile Phe Lys Ile Val Leu Ala Ile</u>	15
		\$ \$ \$ \$ \$ \$	
GNSQ_2882		gtg gat tcc ctg caa ttc tat atg aat ttc gaa tca gtt tgt cga	96
p2882		<u>Val Asp Ser</u> Leu Gln Phe Tyr Met Asn Phe Glu Ser Val Cys Arg	30
		\$ \$	
GNSQ_2882		tgt ctg caa aaa atc tct gtg att ctg ata ggg att gct ttt aac	141
p2882		Cys Leu Gln Lys Ile Ser Val Ile Leu Ile Gly Ile Ala Phe Asn	45
		\$	
GNSQ_2882		ctg tgt aac gat ttg ggg agt att gtc att tta aca gtg tta tgt	186
p2882		Leu Cys Asn Asp Leu Gly Ser Ile Val Ile Leu Thr Val Leu Cys	60
		\$	
GNSQ_2882		att cta atc cat gaa tat gaa ata tat ttc ctt ttg ttt aga tct	231
p2882		Ile Leu Ile His Glu Tyr Glu Ile Tyr Phe Leu Leu Phe Arg Ser	75
GNSQ_2882		ttg att ttt tca tta tgt ttt ata gtt cca gag tat agt aag ttt	276
p2882		Leu Ile Phe Ser Leu Cys Phe Ile Val Pro Glu Tyr Ser Lys Phe	90
		\$	
GNSQ_2882		tgc aat ttt tat gtt aaa ttt att ctt aag aat tta ttt ttg atg	321
p2882		Cys Asn Phe Tyr Val <u>Lys Phe Ile Leu Lys Asn Leu Phe Leu</u> Met	105
GNSQ_2882		cta tca taa	330
p2882		Leu Ser STOP	107
		\$	

Figure 4

GNSQ_4711	tctagg	atg gta act cct atc tgg aca ctt ttc att tgt tac tgt ttg acc	51
p4711		<u>Met Val Thr Pro Ile Trp Thr Leu Phe Ile Cys Tyr Cys Leu Thr</u>	15
		\$ \$	
GNSQ_4711		tct ttg ctt gta tta cag gct ata ttt aaa gaa ata gat aac att	96
p4711		<u>Ser Leu Leu Val Leu Gln Ala</u> Ile Phe Lys Glu Ile Asp Asn Ile	30
		\$ \$ \$ \$	
GNSQ_4711		ctc tct gag gtt gat tta aac caa cat cct gta cgt tgc tgc tat	141
p4711		Leu Ser Glu Val Asp Leu Asn Gln His Pro Val Arg Cys Cys Tyr	45
		\$ \$	
GNSQ_4711		agc ttc cca aca ttt tgt gta gag ggg atg cta ttg aag ttg tgt	186
p4711		Ser Phe Pro Thr Phe Cys Val Glu Gly Met Leu Leu Lys Leu Cys	60
GNSQ_4711		ttt aat atg gag cca cac tgt ttt ctt tct ctg acc cag tct aca	231
p4711		Phe Asn Met Glu Pro His Cys Phe Leu Ser Leu Thr Gln Ser Thr	75
		\$	
GNSQ_4711		gtc agc ctg tcc caa ggc tgc cat cta ttc tct gtg ttt gtg cag	276
p4711		Val Ser Leu Ser Gln Gly Cys <u>His Leu Phe Ser Val Phe Val Gln</u>	90
		\$	
GNSQ_4711		ctc atc tgg aca gct cat ctg gac aga cac aaa gaa tag	315
p4711		Leu Ile Trp Thr Ala His Leu Asp Arg His Lys Glu STOP	102
		\$	

[illegible]

6/11

Figure 6




		forward															
GNSQ_5008	ccagac	atg	atc	ttt	ggc	ctg	cta	atc	aaa	gct	ctt	tat	cta	gcg	tca	gcc	51
p5008		Met	Ile	Phe	Gly	Leu	Leu	Ile	Lys	Ala	Leu	Tyr	Leu	Ala	Ser	Ala	15
		\$			\$	\$	\$		\$								
GNSQ_5008		tgg	gca	ggg	gct	ctg	agc	ctc	ggc	gct	gct	ggc	att	tgg	ggc	tgg	96
p5008		Trp	Ala		Gly	Ala	Leu	Ser	Leu	Gly	Ala	Ala	Gly	Ile	Trp	Gly	30
GNSQ_5008		atg	act	ctt	tgc	tgt	ggc	tgc	tgt	cct	gtg	cat	tac	agg	aca	tta	141
p5008		Met	Thr	Leu	Cys	Cys	Gly	Cys	Cys	Pro	Val	His	Tyr	Arg	Thr	Leu	45
					\$	\$											
GNSQ_5008		cgt	agc	atc	cct	gac	cac	aac	cta	cta	gat	gcc	agt	agc	acc	ccc	186
p5008		Arg	Ser	Ile	Pro	Asp	His	Asn	Leu	Leu	Asp	Ala	Ser	Ser	Thr	Pro	60
GNSQ_5008		tcc	cta	gtt	atg	aca	acc	aga	aac	atc	tcc	aga	cat	tgc	caa	tgt	231
p5008		Ser	Leu	Val	Met	Thr	Thr	Arg	Asn	Ile	Ser	Arg	His	Cys	Gln	Cys	75
														\$			
GNSQ_5008		ccc	ctg	gtg	gca	aaa	tca	tcc	ccg	gct	gag	aat	gag	tgt	tgc	acg	276
p5008		Pro	Leu	Val	Ala	Lys	Ser	Ser	Pro	Ala	Glu	Asn	Glu	Cys	Cys	Thr	90
														\$			
GNSQ_5008		gta	att	cct	cca	ttc	caa	att	aac	aga	gca	ctt	agg	aac	gag	tgc	321
p5008		Val	Ile	Pro	Pro	Phe	Gln	Ile	Asn	Arg	Ala	Leu	Arg	Asn	Glu	Cys	105
		reverse															
GNSQ_5008		ttt	ctc	cta	tta	ctt	tcc	ctt	taa								345
p5008		Phe	Leu	Leu	Leu	Leu	Ser	Leu	STOP								112
									\$								

7/11

Figure 7

		<u>forward</u> →															
GNSQ_0210	tgaact	atg	ggc	ttt	gtt	gtt	cta	tgc	cta	att	ttc	ttc	ctg	tgt	aag	act	51
p0210		Met	Gly	Phe	Val	Val	Leu	Cys	Leu	Ile	Phe	Phe	Leu	Cys	Lys	Thr	15
		\$			\$	\$			\$	\$			\$				
GNSQ_0210		gga	atg	gat	tcc	aga	ttt	caa	cta	aaa	ctc	ttg	ttt	cac	tgt	ttt	96
p0210		<u>Gly</u>	Met	Asp	Ser	Arg	Phe	Gln	Leu	Lys	Leu	Leu	Phe	His	Cys	Phe	30
GNSQ_0210		caa	gga	ctt	ttc	caa	agg	tca	cac	atg	gac	tat	tgt	gat	gaa	tgc	141
p0210		Gln	Gly	Leu	Phe	Gln	Arg	Ser	His	Met	Asp	Tyr	Cys	Asp	Glu	Cys	45
													\$		\$		
GNSQ_0210		act	ctg	cag	ggt	gtg	ttc	cca	gag	cac	aga	agt	aac	cag	aga	gct	186
p0210		Thr	Leu	Gln	Gly	Val	Phe	Pro	Glu	His	Arg	Ser	Asn	Gln	Arg	Ala	60
GNSQ_0210		gca	agg	gag	gtg	ttg	ccc	aca	cca	aaa	cac	tgc	aga	ctt	att	ccc	231
p0210		Ala	Arg	Glu	Val	Leu	Pro	Thr	Pro	Lys	His	Cys	Arg	Leu	Ile	Pro	75
																\$	
GNSQ_0210		ctg	ggg	aca	gtg	ctg	tca	gag	tgt	cca	ttt	caa	gct	ccc	tgt	tgg	276
p0210		Leu	Gly	Thr	Val	Leu	Ser	Glu	Cys	Pro	Phe	Gln	Ala	Pro	Cys	Trp	90
																\$	
GNSQ_0210		cca	cag	aca	aaa	gcc	att	atc	cta	aat	ctc	tgg	cga	aac	ttg	gag	321
p0210		Pro	Gln	Thr	<u>Lys</u>	<u>Ala</u>	<u>Ile</u>	<u>Ile</u>	<u>Leu</u>	<u>Asn</u>	<u>Leu</u>	<u>Trp</u>	<u>Arg</u>	<u>Asn</u>	<u>Leu</u>	<u>Glu</u>	105
GNSQ_0210		gtc	tta	gaa	gtg	gac	aga	agt	tta	aga	cag	gat	tgc	ttt	aaa	tgc	366
p0210		Val	Leu	Glu	Val	Asp	Arg	Ser	Leu	Arg	Gln	Asp	Cys	Phe	Lys	Cys	120
		← <u>reverse</u>															
GNSQ_0210		aca	att	ttg	tta	gaa	ttt	tto	tga								390
p0210		Thr	Ile	Leu	Leu	Glu	Phe	Phe	STOP								127
									\$								

Figure 8

		forward 															
GNSQ_4922	ctgact	atg	atg	agg	gtg	cta	agg	ctg	ctg	gcg	agg	gtc	ctc	ctc	ggc	cag	51
p4922		Met	Met	Arg	Val	Leu	Arg	Leu	Leu	Ala	Arg	Val	Leu	Leu	Gly	Gln	15
		\$				\$		\$	\$			\$	\$	\$			
GNSQ_4922		ctt	ctc	cta	gca	gca	ggg	cac	gca	cag	ccc	tgt	ttt	ctc	atc	tgc	96
p4922		Leu	Leu	Leu	Ala	Ala	Gly	His	Ala	Gln	Pro	Cys	Phe	Leu	Ile	Cys	30
												\$				\$	
GNSQ_4922		ttt	cag	cag	cat	ttg	cct	cct	act	cca	ctt	ggg	tca	ctc	aag	ggg	141
p4922		Phe	Gln	Gln	His	Leu	Pro	Pro	Thr	Pro	Leu	Gly	Ser	Leu	Lys	Gly	45
GNSQ_4922		ccc	aaa	ata	gac	ctg	tgc	att	cat	ggg	acc	cct	ccc	acc	tgc	ctc	186
p4922		Pro	Lys	Ile	Asp	Leu	Cys	Ile	His	Gly	Thr	Pro	Pro	Thr	Cys	Leu	60
							\$										
GNSQ_4922		tct	gct	cag	tgt	ctc	tgt	tgg	gac	agg	cag	caa	gtg	ctt	aaa	tcc	231
p4922		Ser	Ala	Gln	Cys	Leu	Cys	Trp	Asp	Arg	Gln	Gln	Val	Leu	Lys	Ser	75
							\$										
		reverse 															
GNSQ_4922		cag	cca	ctg	ctc	ccc	gct	gga	gtc	cac	ctg	aga	act	ttc	cca	gca	276
p4922		Gln	Pro	Leu	Leu	Pro	Ala	Gly	Val	His	Leu	Arg	Thr	Phe	Pro	Ala	90
																	
GNSQ_4922		att	tga														282
p4922		Ile	STOP														91
		\$															

9/11

Figure 9

N-Terminal Region

CXCL1	MARAALS --AAPSNPR ---LLRVALLLLLLVAAGRRAAG
CXCL2	MARATLS --AAPSNPR ---LLRVALLLLLLVAASRRAAG
CXCL3	MAHATLS --AAPSNPR ---LLRVALLLLLLVG SRRAAGAS
CXCL4	MS --SAF--CASRPG ----LFLGLLLLLPLVAFASA
CXCL5	MSLLSSR --AARVPGPSSSLCALLVLLLLLTQPGPIASA
CXCL6	MSLPSSR --AARVPGPSGLCALLALLLTTPPGPIASA
CXCL7	MSRLDTPSCNSARPLHALQVLLLLLSLLLTALASSTKGQTKRNLAKGKEE
CXCL8	MT ---SKL-A-----V-ALLAAFLI-SAALCEG
CXCL9	MKKSG -----VLELLGIILLVLIGVQG
CXCL10	MNQTA -----I-LICCLIFLTLSGIQG
CXCL11	MSVKGM -----AIALAVILCATVVQG
p1754	MNVI -----VLQFILLVFLVKIYKHADTLFYI
p0711	MVIPH -----LV-LLTLISFRLKEKNSVFH
p2882	MSPS -----L-FFIFKIVLAIVDSL
p0210	MGFVVLCIIFFLCKTGMDSRFQKLLFHCFOGL
p4922	MMR -----VLRLLARVLLGQLLLAA

Cys-rich region

CXCL1	ASVATELRQC --CLQTLQGIHPKN-IQSVNVKSPG -----PHCAQTE--VIATLKNGRKA---C
CXCL2	APLATELRQC --CLQTLQGIHLKN-IQSVVKSPG -----PHCAQTE--VIATLKNGQKA---C
CXCL3	VVTELRQC --CLQTLQGIHLKN-IQSVNVRSFG -----PHCAQTE--VIATLKNGKKA---C
CXCL4	EAEEDGDLQCL --CVKTTQVRPRH-ITSLEVIKAG -----PHCPTAQ--LIATLKNGRK---IC
CXCL5	GPAAAVLRELCV --CLQTTQGVHPKM-ISNLQVFAIG -----PQCSKVE--VVASLKNGKE---IC
CXCL6	GPVSAVLTELRCT --CLRVTLRVNPKT-IGKLQVFPAG -----PQCSKVE--VVASLKNGKQ---VC
CXCL7	SLDSDLYAELRCM --CIKTTSGIHPKN-IQSVLEVIKAG -----THCNQVE--VIATLKDGRK---IC
CXCL8	AVLPRSAKELRCQ --CIKTYSKPFHPKFIKELRVIESG -----PHCANTE--IIVKLSDGRE---LC
CXCL9	TPVVRKGRCS --CISTNQGTIHLQSLKDLKQFAPS -----PSCEKIE--IIATLKNGVQT---C
CXCL10	VPLSRTVRCT --CISISNQPVNPRSLKLEIIPAS -----QFCPRVE--IIATMKKKGEKR---C
CXCL11	FPMFKRGRCCL --CIGPGVKAVKVADIEKASIMYPS -----NNCDKIE--VIITLKENKGQR---C
p1754	YIPIYVCM --CIH-SYALYNSILVSDGLRMLR -----CSHK---IIISTLTITF---LC
p0711	LIFPAIHSCL --CDSGRIPARNALDPSQDQQLQDQDKGTETMCVAGSNLNVHWSVNEERK ---C
p2882	QFYMNFESVCR --CLQKISVIL-IGIAFNLCNDLGS IVILTV-LCILIHEYEYIFLLFRSLIFSLC
p0210	FQRSHMDYCDL --CTLQGVFPEHRSNQRAAREVLPTP -----KHCRLIPLGTVLSECPFPQAP ---C
p4922	GHAQPCFLICFQQHLPTPLGSLKGPKID -----LCIHGTPPTCLSAQC -----LC

C-terminal region

CXCL1	LNPASPIVKKIIEKMLNSDKSN
CXCL2	LNPASPMVKKIIEKMLKNGKSN
CXCL3	LNPASPMVQKIIEKILNKGSTN
CXCL4	LDLQAPLYKKIIEKKLES
CXCL5	LDPEAPFLKKVIQKILDGGNKEN
CXCL6	LDPEAPFLKKVIQKILDSGNKKN
CXCL7	LDPDAPRIKKIVQKKLAGDESAD
CXCL8	LDPKENWVQRVVEKFLKRAENS
CXCL9	LNPDSADVKELIKKEKQVVSQKKKQKNGKKHQQKKVLKVRKSQRSRQKTT
CXCL10	LNPESKAIKNLLKAVSKERSK RSP
CXCL11	LNPKSKQARLIIEKVERKNF
p1754	LHAEILTNGQLPTVFSTPACCTGW
p0711	GISIQCNIIQPLQSRKLCRLQQR
p2882	FIVPEYSKFCNFYVKFILKNFLMLS
p0210	WPQTKAIIILNLRNLEVLEVDRLQDCFKCTILLEFF
p4922	WDRQQVLKSQPLLPAGVHLRTFFAI


CC1 M Q I I T T A L V C L L L A G M W P E D V D S K S M Q V
CC2 M K V S A A L L C L L L I A A T F I P Q G L A Q P P A I N
CC3 M Q V S T A A L A V L L C T M A L C N F S A S L A D
CC4 M K L C V T V L S L L M L V A A F C S P A L S A P M G S D
CC5 M K V S A A A L A V I L I A T A L C A P A S A S P Y S S
CC7 M K S A A L L C L L L T A A A F S P Q G L A Q P V G I N
CC8 M K V S A A L L C L L L M A A T F S P Q G L A Q P D S V S
p4711 M V T P I W T L F I C Y C L T S L L V L Q A I F K E I D N I L S E V D I N Q
p4320 M L F T L L F R I L I G Y V R T L W
p5008 M I P G L L I K A L Y L A S A W A G A L S L G A A G I W G

```
CCL1 PFSRCCSFSAEQEIPLRILCYRN -TSSI-----CSNEGLIFKLRGKEA -CALD
CCL2 APVTCCYNFTNRKISVQRLASYRRITSSK -----CPKEAVIFKTIVAKEI -CAD
CCL3 TPTACCFSYSTRQIPQNFIADYFE -TSSQ-----CSKPGVFILTKRSRV -CAD
CCL4 PPTACCFSYTARKLPRNFVDVYE -TSSL-----CSQPAVFVOTKSRQV -CAD
CCL5 DTPCCFAYIARPLPRAHIKEYFY -TSGK-----CSNPAVFVTRKNRQV -CAN
CCL7 TSPTCCFYFINKKIPKQRLESYRRTTSIH -----CPREAVIFKTKLDKEI -CAD
CCL8 IPI TC CNFNVRNKIPIQRLESYTRITNI -----CPKEAVIFKTKRGKEV -CAD
p4711 HPVRCCYSFPTFCVEGMILLKLCFNMEPH -----CFLSLTQSTVSLSQG --CHL
p4320 TKNSCCCWRMILNHSFKQEVPMLVELKQK -----CEMFCKQYLVDKDYSFRSVSVCQFF
p5008 WMTLCCGCCPVHYRTLRSIPDHNLDDASSTPSLVMTTRNISRHCCQLPAKSSPAENE ---CCTV
```

```
CCL1          TVGWVQRHRKMLRHCPSKRK
CCL2          PKQKWVQDSMDHLDKQTQPKT
CCL3          PSEEWVQKYVSDLELSA
CCL4          PSESWVQEYVYDLELN
CCL5          PEKKWVREYINSLEMS
CCL7          PTQKWVQDFMKHLDKKTQTQPKL
CCL8          PKERWVRDSMKHLLDQIFQNLKP
p4711        FSVFVQLIWTAHLDRIKKE
p4320        ILLHDSYPTNTIPTLSALISSIFL
p5008        IPPFQINRALNECFLLLLSL
```


11/11

Figure 11



SEQUENCE LISTING

<110> Applied Research Systems ARS holding N.V.

5 <120> NOVEL CHEMOKINE-LIKE POLYPEPTIDES

<130> WO582

<160> 52

10

<170> PatentIn version 3.0

<210> 1

<211> 303

15

<212> DNA

<213> Homo sapiens

<400> 1

gaggtaatga atgtcattgt ttacagttt attctcttg tgttcttct tggaagata 60

20

tataagcatg cagacacact atttatata tatataccta tataatgatg tatgtgtata 120

cacagttatg cactgtataa cagtatttg gtcagtgatg gactgcgtat gctaagggtg 180

25

tcccataaga ttataataag tacttgact ataactttc tatgtttaca tgcagaaata 240

cttactaatg gggtacagtt gcctacagta ttacgtacac cagcatgctg tacagggtgg 300

tag

303

30

<210> 2

<211> 98

<212> PRT

<213> Homo sapiens

<400> 2

5 Met Asn Val Ile Val Leu Gln Phe Ile Leu Leu Val Phe Leu Leu Val
1 5 10 15

Lys Ile Tyr Lys His Ala Asp Thr Leu Phe Tyr Ile Tyr Ile Pro Ile
20 25 30

10

Tyr Val Cys Met Cys Ile His Ser Tyr Ala Leu Tyr Asn Ser Ile Leu
35 40 45

Val Ser Asp Gly Leu Arg Met Leu Arg Cys Ser His Lys Ile Ile Ile
15 50 55 60

Ser Thr Leu Thr Ile Thr Phe Leu Cys Leu His Ala Glu Ile Leu Thr
65 70 75 80

20 Asn Gly Leu Gln Leu Pro Thr Val Phe Ser Thr Pro Ala Cys Cys Thr
85 90 95

Gly Trp

25

<210> 3

<211> 336

<212> DNA

<213> Homo sapiens

30

<400> 3

agcattatgg ttattccaca tctgtttta ttgacttga ttcccttag attaaaagaa 60

aaaaatagtg tatttcattt aattttcccc gctattcaca gttatgctt atgtgattct 120

ggaagaattc cagctaggaa tgccttgac ccatcccagg accagcaacc cctgcagcag 180

gacaaagatg gcactgagac tatgtgtgta gctggaagca acctaaatgt ccattcgtgg 240

5

gtgaatgaag aaagaaaatg tggcataatcc atacaatgta atatcattca gcctttacaa 300

agtaggaaac tctgccgttt gctgcaacag agatga 336

10

<210> 4

<211> 109

<212> PRT

<213> Homo sapiens

15

<400> 4

Met Val Ile Pro His Leu Val Leu Leu Thr Leu Ile Ser Phe Arg Leu

1 5 10 15

20

Lys Glu Lys Asn Ser Val Phe His Leu Ile Phe Pro Ala Ile His Ser

20 25 30

Leu Cys Leu Cys Asp Ser Gly Arg Ile Pro Ala Arg Asn Ala Leu Asp

25 35 40 45

Pro Ser Gln Asp Gln Gln Pro Leu Gln Gln Asp Lys Asp Gly Thr Glu

50 55 60

30 Thr Met Cys Val Ala Gly Ser Asn Leu Asn Val His Ser Trp Val Asn

65 70 75 80

Glu Glu Arg Lys Cys Gly Ile Ser Ile Gln Cys Asn Ile Ile Gln Pro

85 90 95

Leu Gln Ser Arg Lys Leu Cys Arg Leu Leu Gln Gln Arg
 100 105

5 <210> 5

<211> 330

<212> DNA

<213> Homo sapiens

10 <400> 5

ggaagtatga gtcctagttt attctcatt ttaagattg tttggctat tgggattcc 60

ctgcaattct atatgaattt cgaatcagtt tgcgatgtc tgcaaaaaat ctctgtgatt 120

15 ctgataggga ttgcttttaa cctgtgtaac gattgggga gtattgcat ttaacagtg 180

ttatgtattc taatccatga atatgaaata tatttccttt tgttiagatc ttgattttt 240

tcattatggt ttatagtcc agagtatagt aagttttgca attttatgt taaatttatt 300

20

cttaagaatt tatttttgat gctatcataa 330

<210> 6

25 <211> 107

<212> PRT

<213> Homo sapiens

<400> 6

30

Met Ser Pro Ser Leu Phe Phe Ile Phe Lys Ile Val Leu Ala Ile Val

1 5 10 15

Asp Ser Leu Gln Phe Tyr Met Asn Phe Glu Ser Val Cys Arg Cys Leu

20 25 30
 Gln Lys Ile Ser Val Ile Leu Ile Gly Ile Ala Phe Asn Leu Cys Asn
 35 40 45
 5
 Asp Leu Gly Ser Ile Val Ile Leu Thr Val Leu Cys Ile Leu Ile His
 50 55 60
 Glu Tyr Glu Ile Tyr Phe Leu Leu Phe Arg Ser Leu Ile Phe Ser Leu
 10 65 70 75 80
 Cys Phe Ile Val Pro Glu Tyr Ser Lys Phe Cys Asn Phe Tyr Val Lys
 85 90 95
 15 Phe Ile Leu Lys Asn Leu Phe Leu Met Leu Ser
 100 105
 <210> 7
 <211> 315
 20 <212> DNA
 <213> Homo sapiens
 <400> 7
 tctaggatgg taactcctat ctggacactt ttcatltgtt actgtttgac ctctttgctt 60
 25 gtattacagg ctatatttaa agaaatagat aacattctct ctgaggttga tttaaacc aa 120
 catcctgtac gtgtctgcta tagcttccca acattttgtg tagaggggat gctattgaag 180
 30 ttgtgtttaa atatggagcc acactgtttt ctttctctga ccagctctac agtcagcctg 240
 tccaaggct gccatctatt ctctgtgttt gtgcagctca tctggacagc tcattctggac 300
 agacacaaag aatag 315

<210> 8

<211> 102

5 <212> PRT

<213> Homo sapiens

<400> 8

10 Met Val Thr Pro Ile Trp Thr Leu Phe Ile Cys Tyr Cys Leu Thr Ser

1 5 10 15

Leu Leu Val Leu Gln Ala Ile Phe Lys Glu Ile Asp Asn Ile Leu Ser

20 25 30

15

Glu Val Asp Leu Asn Gln His Pro Val Arg Cys Cys Tyr Ser Phe Pro

35 40 45

Thr Phe Cys Val Glu Gly Met Leu Leu Lys Leu Cys Phe Asn Met Glu

20 50 55 60

Pro His Cys Phe Leu Ser Leu Thr Gln Ser Thr Val Ser Leu Ser Gln

65 70 75 80

25 Gly Cys His Leu Phe Ser Val Phe Val Gln Leu Ile Trp Thr Ala His

85 90 95

Leu Asp Arg His Lys Glu

100

30

<210> 9

<211> 312

<212> DNA

<213> Homo sapiens

<400> 9
 tgtaatatgt tattacttt attattccga attctaactg gttatgtgag aactctgtgg 60
 5 acgaaaaatt ctgctgctg ttggcgaatg attttaaact attcattaa acaagaagt 120
 cctatgattg tagagctaaa gcaaaaatgt gaaatgttt gtcagaaata tctagtgtat 180
 aaagattatt ccttcgtgt ttctgtaacc tgcagttct ttatacttt acatgattcc 240
 10 tacccaactg agaatacatg gtcaactatt ccaacattgt ctgctcttat atccctcttg 300
 attttctgt ga 312
 15
 <210> 10
 <211> 101
 <212> PRT
 <213> Homo sapiens
 20
 <400> 10
 Met Leu Phe Thr Leu Leu Phe Arg Ile Leu Ile Gly Tyr Val Arg Thr
 1 5 10 15
 25 Leu Trp Thr Lys Asn Ser Cys Cys Cys Trp Arg Met Ile Leu Asn His
 20 25 30
 Ser Phe Lys Gln Glu Val Pro Met Ile Val Glu Leu Lys Gln Lys Cys
 30 35 40 45
 Glu Met Phe Cys Gln Lys Tyr Leu Val Asp Lys Asp Tyr Ser Phe Arg
 50 55 60

Val Ser Val Thr Cys Gln Phe Phe Ile Leu Leu His Asp Ser Tyr Pro
 65 70 75 80

Thr Glu Asn Thr Trp Ser Thr Ile Pro Thr Leu Ser Ala Leu Ile Ser
 5 85 90 95

Ser Leu Ile Phe Leu
 100

10 <210> 11
 <211> 345
 <212> DNA
 <213> Homo sapiens

15 <400> 11
 ccagacatga tctttgcct gctaataaaa gctctttatc tagcgtcagc ctgggcaggg 60
 gctctgagcc tcggcgctgc tggcatttgg ggctggatga ctctttgctg tggctgctgt 120
 20 cctgtgcatt acaggacatt acgtagcatc cctgaccaca acctactaga tgccagtagc 180
 accccctccc tagttatgac aaccagaaac atctccagac attgccaatg tcccctgggtg 240
 gcaaaatcat ccccggtga gaatgagtg tgcacggtaa ttctccatt ccaaattaac 300
 25 agagcactta ggaacgagtg ctttctccta ttacttccc tttaa 345

<210> 12
 30 <211> 112
 <212> PRT
 <213> Homo sapiens
 <400> 12

Met Ile Phe Gly Leu Leu Ile Lys Ala Leu Tyr Leu Ala Ser Ala Trp
 1 5 10 15

5 Ala Gly Ala Leu Ser Leu Gly Ala Ala Gly Ile Trp Gly Trp Met Thr
 20 25 30

Leu Cys Cys Gly Cys Cys Pro Val His Tyr Arg Thr Leu Arg Ser Ile
 35 40 45

10 Pro Asp His Asn Leu Leu Asp Ala Ser Ser Thr Pro Ser Leu Val Met
 50 55 60

Thr Thr Arg Asn Ile Ser Arg His Cys Gln Cys Pro Leu Val Ala Lys
 15 65 70 75 80

Ser Ser Pro Ala Glu Asn Glu Cys Cys Thr Val Ile Pro Pro Phe Gln
 85 90 95

20 Ile Asn Arg Ala Leu Arg Asn Glu Cys Phe Leu Leu Leu Ser Leu
 100 105 110

<210> 13
 <211> 390
 25 <212> DNA
 <213> Homo sapiens

<400> 13
 tgaactatgg gcttgtgtgt tctatgccta atttcttcc tgtgtaagac tggaatggat 60
 30 tccagatttc aactaaaact ctgtttcac tgtttcaag gactttcca aaggtcacac 120
 atggactatt gtgatgaatg cactctgcag ggtgtgtcc cagagcacag aagtaaccag 180

agagctgcaa gggagggtgt gccacacca aaacactgca gacttatcc cctggggaca 240

gtgctgcag agtgtccatt tcaagctccc tgttgccac agacaaaagc cattatccta 300

5 aatctctggc gaaactgga ggtcttagaa gtggacagaa gttaagaca ggattgctt 360

aaatgcacaa tttgttaga attttctga 390

10 <210> 14

<211> 127

<212> PRT

<213> Homo sapiens

15 <400> 14

Met Gly Phe Val Val Leu Cys Leu Ile Phe Phe Leu Cys Lys Thr Gly

1 5 10 15

20 Met Asp Ser Arg Phe Gln Leu Lys Leu Leu Phe His Cys Phe Gln Gly

20 25 30

Leu Phe Gln Arg Ser His Met Asp Tyr Cys Asp Glu Cys Thr Leu Gln

35 40 45

25

Gly Val Phe Pro Glu His Arg Ser Asn Gln Arg Ala Ala Arg Glu Val

50 55 60

Leu Pro Thr Pro Lys His Cys Arg Leu Ile Pro Leu Gly Thr Val Leu

30 65 70 75 80

Ser Glu Cys Pro Phe Gln Ala Pro Cys Trp Pro Gln Thr Lys Ala Ile

85 90 95

Ile Leu Asn Leu Trp Arg Asn Leu Glu Val Leu Glu Val Asp Arg Ser
100 105 110

Leu Arg Gln Asp Cys Phe Lys Cys Thr Ile Leu Leu Glu Phe Phe
5 115 120 125

<210> 15

<211> 282

<212> DNA

10 <213> Homo sapiens

<400> 15

ctgactatga tgagggtgct aaggctgctg gcgaggggtcc tcctcggcca gcttctccta 60

15 gcagcagggc acgcacagcc ctgtttctc atctgcttc agcagcattt gcctcctact 120

ccacttgggt cactcaaggg tccaaaata gacctgtgca ttcattgggac ccctcccacc 180

tgctctctg ctgagtgtct ctgtggggac aggcagcaag tgcttaaatt ccagccactg 240

20

ctccccgctg gaggccacct gagaactttc ccagcaattt ga 282

<210> 16

25 <211> 91

<212> PRT

<213> Homo sapiens

<400> 16

30

Met Met Arg Val Leu Arg Leu Leu Ala Arg Val Leu Leu Gly Gln Leu

1 5 10 15

Leu Leu Ala Ala Gly His Ala Gln Pro Cys Phe Leu Ile Cys Phe Gln

20 25 30

Gln His Leu Pro Pro Thr Pro Leu Gly Ser Leu Lys Gly Pro Lys Ile

35 40 45

5

Asp Leu Cys Ile His Gly Thr Pro Pro Thr Cys Leu Ser Ala Gln Cys

50 55 60

Leu Cys Trp Asp Arg Gln Gln Val Leu Lys Ser Gln Pro Leu Leu Pro

10 65 70 75 80

Ala Gly Val His Leu Arg Thr Phe Pro Ala Ile

85 90

15 <210> 17

<211> 21

<212> DNA

<213> synthetic construct

20 <400> 17

atgaatgtca ttgtttaca g 21

<210> 18

25 <211> 20

<212> DNA

<213> synthetic construct

<400> 18

30 ctaccaacct gtacagcatg 20

<210> 19

<211> 25

<212> DNA

<213> synthetic construct

<400> 19

5 ctgactatga tgagggtgct aaggc

25

<210> 20

<211> 25

10 <212> DNA

<213> synthetic construct

<400> 20

15 tcaaattgct gggaaagttc tcagg

25

<210> 21

<211> 22

<212> DNA

20 <213> synthetic construct

<400> 21

catgatcttt ggccgtgctaa tc

22

25

<210> 22

<211> 20

<212> DNA

<213> synthetic construct

30

<400> 22

accgtgcaac actcattctc

20

<210> 23
<211> 22
<212> DNA
<213> synthetic construct

5

<400> 23
ctatgggctt tgtgttcta tg 22

10 <210> 24
<211> 23
<212> DNA
<213> synthetic construct

15 <400> 24
tcagaaaaat tctaacaaaa ttg 23

20 <210> 25
<211> 19
<212> DNA
<213> synthetic construct

25 <400> 25
atggttattc cacatcttg 19

30 <210> 26
<211> 21
<212> DNA
<213> synthetic construct

<400> 26
tcatctctgt tgcagcaaac g 21

<210> 27
<211> 21
5 <212> DNA
<213> synthetic construct

<400> 27
atgttattta cttattatt c 21
10

<210> 28
<211> 20
<212> DNA
15 <213> synthetic construct

<400> 28
tcacagaaaa atcaaagagg 20

20
<210> 29
<211> 37
<212> DNA
<213> synthetic construct

25
<400> 29
aagcaggcct cgccaccatg aatgtcattg ttttaca 37

30 <210> 30
<211> 32
<212> DNA
<213> synthetic construct

<400> 30
gtgatggtga tgggtccaac ctgtacagca tg 32

5 <210> 31
<211> 42
<212> DNA
<213> synthetic construct

10 <400> 31
aagcaggctt cgccaccctg actatgatga ggggtctaag gc 42

<210> 32
15 <211> 37
<212> DNA
<213> synthetic construct

<400> 32
20 gtgatggtga tggtgaattg ctgggaaagt tctcagg 37

<210> 33
<211> 39
25 <212> DNA
<213> synthetic construct

<400> 33
aagcaggctt cgccacccat gatcttggc ctgctaac 39
30

<210> 34
<211> 33
<212> DNA

<213> synthetic construct

<400> 34
gtgatgggga tgggaagg aaagtaatag gag 33

5

<210> 35
<211> 39
<212> DNA

10 <213> synthetic construct

<400> 35
aagcaggcct cgccacccta tgggcttgt tgttctatg 39

15

<210> 36
<211> 35
<212> DNA
<213> synthetic construct

20

<400> 36
gtgatgggga tggggaaaa attctaaca aattg 35

25 <210> 37
<211> 36
<212> DNA
<213> synthetic construct

30 <400> 37
aagcaggcct cgccaccatg gtattccac atcttg 36

<210> 38

<211> 33

<212> DNA

<213> synthetic construct

5 <400> 38

gtgatgggta tgggtgtctt gttgcagcaa acg 33

<210> 39

10 <211> 38

<212> DNA

<213> synthetic construct

<400> 39

15 aagcaggctt cgccaccatg ttattactt tattattc 38

<210> 40

<211> 32

20 <212> DNA

<213> synthetic construct

<400> 40

25 gtgatgggta tgggtgcagaa aaatcaaaga gg 32

<210> 41

<211> 57

<212> DNA

30 <213> synthetic construct

<400> 41

ggggacaagt ttgtacaaaa aagcaggctt cgccaccatg aatgtcattg ttttaca 57

<210> 42
<211> 68
<212> DNA
5 <213> synthetic construct

<400> 42
ggggaccact ttgtacaaga aagctgggtt tcaatgggtga tggatgatggg gccaacctgt 60
10 acagcatg 68

<210> 43
<211> 62
15 <212> DNA
<213> synthetic construct

<400> 43
ggggacaagt ttgtacaaaa aagcaggcctt cgccaccctg actatgatga ggggtgctaag 60
20 gc 62

<210> 44
25 <211> 73
<212> DNA
<213> synthetic construct

<400> 44
30 ggggaccact ttgtacaaga aagctgggtt tcaatgggtga tggatgatggg gaattgctgg 60
gaaagtcttc agg 73

<210> 45

<211> 59

<212> DNA

<213> synthetic construct

5

<400> 45

ggggacaagt ttgtacaaaa aagcaggctt cgccacccat gatcttggc ctgctaac 59

10 <210> 46

<211> 69

<212> DNA

<213> synthetic construct

15 <400> 46

ggggaccact ttgtacaaga aagctgggtt tcaatgggta tggatgatgt gaagggaag 60

taataggag

69

20

<210> 47

<211> 59

<212> DNA

<213> synthetic construct

25

<400> 47

ggggacaagt ttgtacaaaa aagcaggctt cgccacccta tgggcttgt tgttctatg 59

30 <210> 48

<211> 71

<212> DNA

<213> synthetic construct

<400> 48
ggggaccact ttgtacaaga aagctgggtt tcaatgggtga tggatgatggg ggaaaaattc 60

taacaaaatt g 71

5

<210> 49
<211> 56
<212> DNA
10 <213> synthetic construct

<400> 49
ggggacaagt ttgtacaaaa aagcaggctt cgccaccatg gtattccac atcttg 56

15

<210> 50
<211> 69
<212> DNA
<213> synthetic construct

20

<400> 50
ggggaccact ttgtacaaga aagctgggtt tcaatgggtga tggatgatggg gtctctgttg 60

cagcaaacg 69

25

<210> 51
<211> 58
<212> DNA
30 <213> synthetic construct

<400> 51
ggggacaagt ttgtacaaaa aagcaggctt cgccaccatg ttatttactt tattattc 58

<210> 52

<211> 68

<212> DNA

5 <213> synthetic construct

<400> 52

ggggaccact ttgtacaaga aagctgggtt tcaatgggtga tggatgatgg gcagaaaaat 60

10 caaagagg

68

(19) World Intellectual Property
Organization
International Bureau



01 APR 2005



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031233 A3

(51) International Patent Classification⁷: **C07K 14/52**,
C12N 15/19, A61K 38/19, A01K 67/027, G01N 33/53,
C12Q 1/68, A61K 31/7088, C12N 15/62, 15/11

(21) International Application Number:
PCT/EP2003/050668

(22) International Filing Date:
29 September 2003 (29.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02022270.9 4 October 2002 (04.10.2002) EP

(71) Applicant (for all designated States except US): **AP-
PLIED RESEARCH SYSTEMS ARS HOLDING N.V.**
[NL/NL]; Pietermaai 15, Curacao (AN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **IBBERSON**,
Mark [GB/CH]; Chemin Planet 41, CH-1188 Gimel
(CH). **POWER**, Christine [GB/FR]; Rue des Jonquilles
10, F-01710 Thoiry (FR). **FRAUENSCHUH**, Achim
[DE/CH]; Chemin de Voirets 1, CH-1228 Plan-les-Ouates
(CH).

(74) Agent: **SERONO INTERNATIONAL SA INTELLEC-
TUAL PROPERTY**; Chemin des Aulx 12, CH-1228 Plan-
les-Ouates (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
14 October 2004

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 25/2004 of 17 June 2004, Section II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL CHEMOKINE-LIKE POLYPEPTIDES

(57) Abstract: The present invention discloses open reading frames (ORFs) in human genome encoding for novel chemokines-like polypeptides, and reagents related thereto including variants, mutants and fragments of said polypeptides, as well as ligands and antagonists directed against them. The invention provides methods for identifying and making these molecules, for preparing pharmaceutical compositions containing them, and for using them in the diagnosis, prevention and treatment of diseases.



WO 2004/031233 A3

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/EP 50668

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/52 C12N15/19 A61K38/19 A01K67/027 G01N33/53
 C12Q1/68 A61K31/7088 C12N15/62 C12N15/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBL, BIOSIS, PAJ, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE EMBL 'Online! HTG; DNA Human 124964bp 7 March 2000 (2000-03-07), BATES K.: "human DNA sequence from clone RP11-428G23 on chromosome 13" XP002231616 retrieved from EBI Database accession no. AL159154 the whole document	1-41
A	----- DATABASE EMBL 'Online! 26 June 2001 (2001-06-26), OTA T ET AL.: "Human protein sequence SEQ.ID N 12610" XP002231850 retrieved from EBI Database accession no. AAB93409 the whole document -/--	1-41

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

24 March 2004

Date of mailing of the international search report

19. 08. 04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Perez, C

INTERNATIONAL SEARCH REPORT

Internati ication No
PCT/EP /50668

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>& EP 1 074 617 A (HELIX RES INST) 7 February 2001 (2001-02-07) SEQ:ID n 12610</p> <p>-----</p> <p>HAN WENLING ET AL: "Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity." BIOCHEMICAL JOURNAL, vol. 357, no. 1, 2001, pages 127-135, XP002231615 ISSN: 0264-6021 the whole document</p>	1-41
A	<p>-----</p> <p>WELLS T N C ET AL: "THE CHEMOKINE INFORMATION SOURCE: IDENTIFICATION AND CHARACTERIZATION OF NOVEL CHEMOKINES USING THE WORLDWIDWEB AND EXPRESSED SEQUENCE TAG DATABASES" JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 61, May 1997 (1997-05), pages 545-550, XP002925964 ISSN: 0741-5400 cited in the application the whole document</p>	1-41
A	<p>-----</p> <p>BAGGIOLINI M: "CHEMOKINES IN PATHOLOGY AND MEDICINE" JOURNAL OF INTERNAL MEDICINE, OXFORD, GB, vol. 250, no. 2, August 2001 (2001-08), pages 91-104, XP001021499 ISSN: 0954-6820 cited in the application the whole document</p> <p>-----</p>	1-41

INTERNATIONAL SEARCH REPORT

Inter. Application No.
 PCT/EP 03/50 668

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 31 and 35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 7-11, 13, 24-25, 27-35, 39-41 searched incompletely
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-41 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claims 31 and 35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 7-11, 13, 24-25, 27-35, 39-41 searched incompletely

Present claims 7-11, 13, 24-25, 27-35, 39, 41 relate to a product/compound defined by reference to a desirable characteristic or a property namely a ligand, an antagonist or an agonist . The claims cover all products/compounds having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such products/compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the product/compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibodies, peptide mimetics (claims 12), antisenses and small interfering RNAs (claim 26).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/E/3/50668

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1074617	A	07-02-2001	AU 6180800 A	19-02-2001
			AU 6180900 A	19-02-2001
			AU 6181000 A	19-02-2001
			AU 6181100 A	19-02-2001
			AU 6181200 A	19-02-2001
			AU 6181300 A	19-02-2001
			AU 6181400 A	19-02-2001
			AU 6181500 A	19-02-2001
			AU 6181600 A	19-02-2001
			AU 6315800 A	19-02-2001
			CA 2380472 A1	08-02-2001
			EP 1074617 A2	07-02-2001
			EP 1205549 A1	15-05-2002
			WO 0109315 A1	08-02-2001
			WO 0109345 A1	08-02-2001
			WO 0109316 A1	08-02-2001
			WO 0109349 A1	08-02-2001
			WO 0109317 A1	08-02-2001
			WO 0109318 A1	08-02-2001
			WO 0109319 A1	08-02-2001
			WO 0109346 A1	08-02-2001
			WO 0109320 A1	08-02-2001
			WO 0109321 A1	08-02-2001
			WO 0109322 A1	08-02-2001
			WO 0109323 A1	08-02-2001
			JP 2002171977 A	18-06-2002
			JP 2002191363 A	09-07-2002
			US 2003157569 A1	21-08-2003
			US 2003082776 A1	01-05-2003
			US 2003017480 A1	23-01-2003